Methods and systems for sensitive and multiplexed analysis of biological samples using cleavable fluorescent styramide and probe stripping

Abstract

Provided herein are methods for multiplexed in situ analysis of biomolecules in a tissue. In particular, provided herein are methods for multiplexed single-cell in situ protein and nucleic acid profiling in fixed or fresh tissues, and also allows the investigation of the different cell compositions and their spatial organizations in intact tissues through consecutive cycles of probe hybridization, fluorescence imaging, and signal removal.

Description

METHODS AND SYSTEMS FOR SENSITIVE AND MULTIPLEXED ANALYSIS OF BIOLOGICAL SAMPLES USING CLEAVABLE FLUORESCENT STYRAMIDE AND PROBE STRIPPINGCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Patent Application Serial No. 63 / 666,910, filed July 2, 2024, which is hereby incorporated by reference in its entirety.FIELD OF INVENTION

[0001] The present invention relates the field of molecular biology, and more particular, to methods and systems for analyzing biological samples using cleavable fluorescent styramide agents.BACKGROUND

[0002] The ability to comprehensively profile proteins, nucleic acids, and other biomolecules in intact tissue in situ is crucial to understand the molecular mechanisms underlying cancer, neuroscience, and stem cell biology. The differences between individual cells in complex biological systems may have significant consequences in the function and health of the entire systems. The precise location of multiple, varied biomolecules in a tissue or cell is critical for understanding the spatial organization, gene expression regulation, and interactions of diverse cell types in complex multicellular organisms. However, most of the existing methods for in situ analysis of proteins, nucleic acids, and other biomolecules can only quantify a small number of different molecules in a biological sample. Conventional protein imaging methodologies such as immunohistochemistry (IHC) and immunofluorescence (IF) only allow a handful of proteins to be detected in one tissue sample, and the methods may miss transcripts present at low copy numbers. Accordingly, there remains a need in the art for highly sensitive and multiplexed approaches to in situ protein and nucleic acids analysis.SUMMARY

[0003] The present disclosure overcomes the aforementioned drawbacks by providing low-cost, high-throughput, comprehensive, and highly sensitive and high-quality methods for in situ molecular profiling capable of in situ analysis of target biomolecules (e.g., proteins, nucleic acids) in intact tissues with single-molecule sensitivity.

[0004] In some embodiments, there is provided herein a cleavable detectably-labeled tyramide(CLT) comprising the compound of Formula (I), wherein R is a detectable marker.Formula (I).

[0005] In some embodiments, there is provided herein a cleavable detectably-labeled styramide (CLST) comprising the compound of Formula (IV), wherein R is a detectable marker.

[0006] Exemplary detectable makers include, without limitation, fluorophores, luminescent agents (e.g., chemiluminescent agents), fluorescent proteins, and radioisotopes. By way of example, detectable markers include Cy5, sulfonated cy5, TAMRA (labeled with tetramethylrhodamine or “TMR”), ALEXA FLUOR™ 594, and ATTO 647N and ATTO 700 fluorophores (ATTO-TEC, Germany). Other fluorophores appropriate for use according to the compositions and methods provided herein include, without limitation, quantum dots, ALEXA FLUOR™ 350, ALEXA FLUOR™ 532, ALEXA FLUOR™ 546, ALEXA FLUOR™ 568, ALEXA FLUOR™ 647, BODIPY 493 / 503, BODIPY FL, BODIPY R6G, BODIPY 530 / 550, BODIPY TMR, BODIPY 558 / 568, BODIPY 558 / 568, BODIPY 564 / 570, BODIPY 576 / 589, BODIPY 581 / 591, BODIPY 630 / 650, BODIPY 650 / 665, Cascade Blue, Cascade Yellow, Dansyl, lissamine rhodamine B, Marina Blue, Oregon Green 488, Oregon Green 514, Pacific Blue, rhodamine 6G, rhodamine green, rhodamine red, tetramethyl rhodamine, DYLIGHT™ DYES (e g., DYLIGHT™ 405, DYLIGHT™ 488, DYLIGHT™ 549, DYLIGHT™ 594, DYLIGHT™ 633, DYLIGHT™ 649, DYLIGHT™ 680, DYLIGHT™ 750, DYLIGHT™ 800 and the like), Texas Red, and Cy2, Cy3.5, Cy5.5, and Cy7, and sulfonated Cy2, Cy3.5, Cy5, Cy5.5, and Cy7. In some embodiments, the detectable marker is a sulfonated Cy 5.

[0007] In some embodiments, there is provided a cleavable detectably-labeled tyramide (CLT) comprising the compound of Formula (II):

[0008] In some embodiments, there is provided a cleavable detectably-labeled styramide (CLST) comprising the compound of Formula (V):

[0009] In some embodiments, provided herein is a method of multiplexed in situ analysis of biomolecules in a tissue. In some embodiments, the methods comprise, consist, or consist essentially of the following steps: (a) contacting the tissue with a plurality of horseradish peroxidase (HRP)-conjugated targeting agents that are configured to specifically bind or hybridize to the target biomolecule in the contacted tissue, wherein the second contacting step occurs under conditions that promote binding or hybridization of the targeting agents to the target biomolecule;(b) contacting the tissue with the cleavable detectably-labeled tyramide (CLT) compound of Formula I, or the cleavable detectably-labeled styramide (CLST) compound of Formula IV, under conditions that promote conjugation of the cleavable labeled tyramide to the target biomolecule;(c) imaging the tissue thereby detecting the detectable marker; (d) contacting the tissue sample with a composition comprising l,3,5-Triaza-7-phosphaadamantane (PTA) and tris(2- carboxyethyl)phosphine (TCEP), e.g., at about 40°C for about 30 minutes; and (e) repeating steps (a) - (d); wherein a second plurality of HRP-conjugated targeting agents is used to bind to or hybridize to a second target biomolecule, wherein the first and the second target biomolecules are different. In some embodiments, the HRP-conjugated targeting agent is stripped from the sample. In some embodiments, stripping comprises the use of one or more of a buffer, denaturing agent, detergent, temperature condition, pH condition, osmolarity agent.

[0010] In some embodiments, the method further comprises repeating steps (a)-(d) N times, wherein the Nth plurality of HRP-conjugated targeting agents is used to bind to or hybridize to the Nth target biomolecule, wherein the first through the Nth target biomolecules are different.

[0011] The plurality of biomolecules can comprise proteins, RNA, or DNA, or a combination thereof.

[0012] In some embodiments, the CLT comprises the compound of Formula II.

[0013] In some embodiments, the CLST comprises the compound of Formula IV.

[0014] In some embodiments, provided herein is a kit of CLT for detecting target biomolecules in a cell sample. The kit can comprise, consist, or consist essentially of a cleavable detectably- labeled tyramide comprising the compound of Formula I or Formula II, and a written insert component comprising instructions for performing multiplexed in situ analysis of target biomolecules according to methods of this disclosure.

[0015] In some embodiments, provided herein is a kit of CLST for detecting target biomolecules in a cell sample. The kit can comprise, consist, or consist essentially of a cleavable detectably-labeled styramide comprising the compound of Formula IV or Formula V, and a written insert component comprising instructions for performing multiplexed in situ analysis of target biomolecules according to methods of this disclosure.

[0016] In some embodiments, the kit can further comprise a plurality of HRP-conjugated targeting agents configured to bind or hybridize to a target biomolecule. The plurality of HRP- conjugated targeting agents can comprise HRP-conjugated synthetic DNA oligonucleotide probes. The plurality of HRP-conjugated targeting agents can comprise HRP-conjugated polyclonal or monoclonal antibodies, or antigen-binding fragments thereof. The kit can further comprise tris(2- carboxyethyljphosphine (TCEP), and l,3,5-Triaza-7-phosphaadamantane (PTA), either as separate components or as a composition, and the written instruction component can further comprise instructions for removing the detectable label from the detectably-labeled tyramide using the TCEP and the PTA.

[0017] The foregoing and other advantages of the invention will appear from the following description. In the description, reference is made to the accompanying drawings which form a part hereof, and in which there is shown by way of illustration a preferred embodiment of the invention. Such embodiment does not necessarily represent the full scope of the invention, however, and reference is made therefore to the claims and herein for interpreting the scope of the invention.BRIEF DESCRIPTION OF THE DRAWINGS

[0018] The patent or patent application file contains at least one drawing in color. Copies of this patent or patent application publication with color drawings will be provided by the Office upon request and payment of the necessary fee.

[0019] FIG. 1A-D. (A) Multiplexed in situ protein profiling with high-performance cleavable fluorescent tyramide. After staining protein targets with HRP conjugated antibodies and cleavable fluorescent tyramide, images are captured for protein profiling. Subsequently, a mild chemical reaction is applied to cleave the fluorophores and deactivate HRP simultaneously. Upon reiterative cycles of protein staining, imaging, fluorophore removal and HRP deactivation, multiplexed protein analysis can be achieved in individual cells in situ. (B) Chemical structure of high- performance cleavable fluorescent tyramide, tyramide-N3-Cy5. (C) Multiplexed in situ protein profiling with high-performance cleavable fluorescent styramide. After staining protein targets with HRP conjugated antibodies and cleavable fluorescent styramide, images are captured for protein profiling. Subsequently, a mild chemical reaction is applied to cleave the fluorophores and deactivate HRP simultaneously. Upon reiterative cycles of protein staining, imaging, fluorophore removal and HRP deactivation, multiplexed protein analysis can be achieved in individual cells in situ. (D) Chemical structure of high-performance cleavable fluorescent styramide, styramide-Ns- Cy5.

[0020] FIG. 2A-C. (A) Protein ILF3 in a human tonsil FFPE tissue is stained with tyramide- N3-Cy5. (B) The fluorescence signal is removed by PTA and TCEP. (C) Fluorescence intensity profile corresponding to the red and green line positions in (A) and (B). Scale bars, 10 pm.

[0021] FIG. 3A-C. (A) Protein ILF3 in in a human tonsil FFPE tissue is directly stained with tyramide-N3-Cy5. (B) After the overnight PTA incubation, Protein ILF3 in in a human tonsil FFPE tissue is stained with tyramide-N3-Cy5. (C) Fluorescence intensity of ILF3 staining in (A) and (B) (n = 30 positions). Scale bars, 10 pm.

[0022] FIG. 4. 10 proteins in HeLa cells are stained with tyramide-N3-Cy5 (the first column). Subsequently, the staining signals are removed by PTA and TCEP (the second column). Then, the cells are re-incubated with tyramide-N3-Cy5 (the third column). The fourth column shows the signal intensity profiles corresponding to the red, orange and green line positions in the first three columns. Scale bars, 15 pm.

[0023] FIG. 5A-B. (A) 10 proteins are sequentially stained in the same set of HeLa cells with tyramide-N3-Cy . (B) 10 proteins are individually stained in different HeLa cells with conventional TSA. Scale bars, 50 pm.

[0024] FIG. 6A-B. (A) Mean expression level per cell (n = 100 cells) of the 10 proteins quantified by tyramide-N3-Cy5 and conventional TSA. (B) Comparison of the results obtained by tyramide-N3-Cy5 and TSA yields R2= 0.99 with a slope of 1.09.

[0025] FIG. 7A-B. (A) Histograms of the expression level per cell for the 10 proteins stained in HeLa cells. (B) Pair- wise correlation of the expression levels of the 10 proteins and the hierarchical clustering tree. In the upper triangle, the expression correlation coefficients of every protein pair are shown. In the lower triangle, the color corresponds to the correlation coefficients of each protein pair. The diagonal displays the names of the proteins. With a threshold on the cluster tree (dashed line), a group of proteins with high expression correlation are identified and indicated by the red lines on the clustering tree and the black box in the matrix.

[0026] FIG. 8A-D. (A) In the order of increasing expression levels, three proteins are sequentially stained in a human tonsil FFPE tissue. (B) The three proteins are stained by conventional TSA in three different human tonsil FFPE tissues. (C) In the order of decreasing expression levels, the same three proteins are sequentially stained in a human tonsil FFPE tissue. (D) Fluorescence intensity of the three proteins stained in (A), (B) and (C) (n = 50 positions). Scale bars, 10 pm.

[0027] FIG 9A-B. Ultrasensitive and multiplexed protein imaging with cleavable fluorescent tyramide (CFT) and antibody stripping. (A) In each cycle, multiple protein targets are first recognized by primary antibodies from different species or of varied immunoglobulin classes. Subsequently, the first target is stained by HRP conjugated primary or secondary antibodies and CFT. After imaging, the fluorophores are chemically cleaved and HRP is deactivated simultaneously. The processes of protein staining, fluorescence imaging, fluorophore cleavage and HRP deactivation are repeated until every target in the first cycle is stained. Finally, all the antibodies are stripped to initiate the next cycle. Through reiterative analysis cycles, a large number of distinct proteins can be quantitatively profiled in single cells in situ. (B) Structure of CFT, tyramide-N3-Cy5.

[0028] FIG 10: Different proteins are stained with HRP conjugated antibodies and CFT in FFPE tonsil tissues (the first column). Then, the staining signals are erased by PTA and TCEP (the second column). After antibody stripping, the tissues are re-incubated with HRP conjugated secondary antibodies and CFT (the third column). The fourth column displays the fluorescence intensity profiles corresponding to the red, orange and green line positions in the first three columns. Scale bars, 20 pm.

[0029] FIG 11 : (A) Protein hnRNP K, NPM 1 and Bcl2 are stained with CFT in the same FFPE tonsil tissue after 10, 15 and 20 cycles of antibody stripping, respectively (top row). These proteins are also stained in three different FFPE tonsil tissues by the conventional tyramide signal amplification approach (bottom row). (B) Comparison of the staining intensities obtained after antibody stripping and by conventional immunofluorescence (n = 50 positions). Error bars, standard deviation. Scale bars, 20 pm.

[0030] FIG 12: (A) microscopic photos of 20 different proteins are stained with CFT in the same FFPE tonsil tissue. Scale bars, 500 pm. (B) Zoomed-in views of the boxed area in (A). Scale bars, 100 pm.

[0031] FIG 13: (A) Based on their different single cell protein expression profiles, (B) -67,000 individual cells in the human tonsil tissue are partitioned into 10 cell clusters. (C) Anatomical locations of each cell from the 10 clusters. Scale bars, 500 pm.

[0032] FIG 14: (A) Cell cluster to cell cluster interaction strength heatmap. The upper triangle shows the correlation coefficient of the cell numbers in the identified cell neighborhoods. The lower triangle displays the color corresponding to the correlation coefficient. (B) Based on their neighbor cells from different clusters, (C) the individual cells in cluster 10 are further partitioned into 3 subclusters. (D) Anatomical locations of each cell from the 3 subclusters.

[0033] FIG 15: Single cell protein expression distribution in viSNE plots.

[0034] FIG 16: Anatomical locations of the individual cells from the 10 different cell clusters.

[0035] FIG 17: Further classification of the cells in varied microenvironment. For each cell cluster, based on their neighbor cells from different clusters (upper left), the individual cells in the every cell cluster are further partitioned into distinct subclusters (bottom left). The panels on the right display the anatomical locations of each cell from the different subclusters.

[0036] FIG 18 shows a multiplex in situ proteins (CD4, CD8, FOXP3) and RNAs (PPIB) profding of human tonsil FFPE tissue with cleavable detectably-labeled tyramide / styramide.DETAILED DESCRIPTION

[0037] The invention will now be described more fully hereinafter with reference to the accompanying drawings, in which exemplary embodiments of the invention are shown. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that thisinvention will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art. Like reference numerals refer to like elements throughout.

[0038] The terms used in this specification generally have their ordinary meanings in the art, within the context of the invention, and in the specific context where each term is used. Certain terms that are used to describe the invention are discussed below, or elsewhere in the specification, to provide additional guidance to the practitioner regarding the description of the invention. For convenience, certain terms may be highlighted, for example using italics and / or quotation marks. The use of highlighting has no influence on the scope and meaning of a term; the scope and meaning of a term is the same, in the same context, whether or not it is highlighted. It will be appreciated that same thing can be said in more than one way. Consequently, alternative language and synonyms may be used for any one or more of the terms discussed herein, nor is any special significance to be placed upon whether or not a term is elaborated or discussed herein. Synonyms for certain terms are provided. A recital of one or more synonyms does not exclude the use of other synonyms. The use of examples anywhere in this specification including examples of any terms discussed herein is illustrative only, and in no way limits the scope and meaning of the invention or of any exemplified term. Likewise, the invention is not limited to various embodiments given in this specification.

[0039] One of ordinary skill in the art will appreciate that starting materials, biological materials, reagents, synthetic methods, purification methods, analytical methods, assay methods, and biological methods other than those specifically exemplified can be employed in the practice of the invention without resort to undue experimentation. All art-known functional equivalents, of any such materials and methods are intended to be included in this invention. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims.

[0040] Whenever a range is given in the specification, for example, a temperature range, a time range, or a composition or concentration range, all intermediate ranges and subranges, as well asall individual values included in the ranges given are intended to be included in the invention. It will be understood that any subranges or individual values in a range or subrange that are included in the description herein can be excluded from the claims herein.

[0041] As used herein and in the appended claims, the singular forms “a”, “an” and “the” include plural reference, unless the context clearly dictates otherwise. Thus, for example, reference to “a cell” includes a plurality of such cells and equivalents thereof known to those skilled in the art, and so forth. As well, the terms “a” (or “an”), “one or more” and “at least one” can be used interchangeably herein. In addition, the terms “comprising”, “including” and “having” can be used interchangeably.

[0042]

[0043] It will be understood that when an element is referred to as being “on”, “attached” to, “connected” to, “coupled” with, “contacting”, etc., another element, it can be directly on, attached to, connected to, coupled with or contacting the other element or intervening elements may also be present. In contrast, when an element is referred to as being, for example, “directly on”, “directly attached” to, “directly connected” to, “directly coupled” with or “directly contacting” another element, there are no intervening elements present. It will also be appreciated by those of skill in the art that references to a structure or feature that is disposed “adjacent” another feature may have portions that overlap or underlie the adjacent feature.

[0044] It will be understood that, although the terms first, second, third etc. may be used herein to describe various elements, components, regions, layers and / or sections, these elements, components, regions, layers and / or sections should not be limited by these terms. These terms are only used to distinguish one element, component, region, layer or section from another element, component, region, layer or section. Thus, a first element, component, region, layer or section discussed below could be termed a second element, component, region, layer or section without departing from the teachings of the invention.

[0045] Furthermore, relative terms, such as “lower” or “bottom” and “upper” or “top,” may be used herein to describe one element’s relationship to another element as illustrated in the figures. It will be understood that relative terms are intended to encompass different orientations of the device in addition to the orientation depicted in the figures. For example, if the device in one of the figures is turned over, elements described as being on the “lower” side of other elements would then be oriented on “upper” sides of the other elements. The exemplary term “lower”, can therefore, encompasses both an orientation of “lower” and “upper,” depending of the particular orientationof the figure. Similarly, if the device in one of the figures is turned over, elements described as “below” or “beneath” other elements would then be oriented “above” the other elements. The exemplary terms “below” or “beneath” can, therefore, encompass both an orientation of above and below.

[0046] It will be further understood that the terms “comprises” and / or “comprising”, or “includes” and / or “including”, or “has” and / or “having”, or “carry” and / or “carrying”, or “contain” and / or “containing”, or “involve” and / or “involving”, “characterized by”, and the like are to be open-ended, i.e., to mean including but not limited to. When used in this disclosure, they specify the presence of stated features, regions, integers, steps, operations, elements, and / or components, but do not preclude the presence or addition of one or more other features, regions, integers, steps, operations, elements, components, and / or groups thereof.

[0047] Unless otherwise defined, all terms (including technical and scientific terms) used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. It will be further understood that terms, such as those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the relevant art and the invention, and will not be interpreted in an idealized or overly formal sense unless expressly so defined herein.

[0048] As used in the disclosure, “around”, “about”, “approximately” or “substantially” means within 10% of a stated concentration range or within 10% of a stated time frame.

[0049] As used in the disclosure, the phrase “at least one of A, B, and C” should be construed to mean a logical (A or B or C), using a non-exclusive logical OR. As used herein, the term “and / or” includes any and all combinations of one or more of the associated listed items.

[0050] As used in the disclosure, the term “multiplexed” refers to the detection of multiple signals (e.g., two or more signals), such as, for example, analytes, fluorescent signals, analog or digital signals, that are combined into one signal over a shared medium. The term encompasses the detection of multiple signals simultaneously in a single sample or single reaction vessel, as well as the combining of images of multiple signals to obtain one image that reflects the combination.

[0051] As used in the disclosure, the terms “target biomolecule”, “target molecule”, and “target” refer to a protein or peptide, a nucleic acid (e.g., DNA, RNA), or a carbohydrate which are to be bind by a targeting agent (detection agent), e.g., a HRP-conjugated antibody or oligonucleotides.

[0052] As used in the disclosure, the terms “detection agent” and “targeting agent” refer to a conjugate of a functional group to an antibody, an oligonucleotide, or other molecules which specifically bind to a target biomolecule, e.g., HRP-conjugated antibody or oligonucleotides.

[0053] As used in the disclosure, the terms “binding,” “to bind,” “binds,” “bound,” or any derivation thereof refers to any stable, rather than transient, chemical bond between two or more molecules, including, but not limited to, covalent bonding, ionic bonding, and hydrogen bonding. The term “binding” encompasses interactions between polypeptides, for example, an antibody and its epitope on a target protein. The term also encompasses interactions between a nucleic acid molecule and another entity such as a nucleic acid or probe element. Specifically, binding, in certain embodiments, includes the hybridization of nucleic acids.

[0054] As used in the disclosure, the term “blocking” refers to treatment of a sample with a composition that prevents the non-specific binding of the target substance to the sample.

[0055] As used in the disclosure, the term “stripping” refers to the process of interfering with the non-covalent binding between a target biomolecule in a sample and a detection agent such that significant amounts of targeting agent / detection agent (e.g. a HRP-conjugated antibody or oligonucleotides) is eluted or “stripped” away from the in situ sample.

[0056] As used in the disclosure, the term “biological entity” as used herein means any independent organism or thing, alive or dead, containing genetic material (e.g., nucleic acid) that is capable of replicating either alone or with the assistance of another organism or cell. Sources for nucleic acid-containing biological entities include, without limitation, an organism or organisms including a cell or cells, bacteria, yeast, fungi, algae, viruses, or a sample thereof.

[0057] As used in the disclosure, the term “sample” include all types of cell culture, animal or plant tissue, peripheral blood lymphocytes, buccal smears, touch preparations prepared from uncultured primary tumors, cancer cells, bone marrow, cells obtained from biopsy or cells in bodily fluids (e.g., blood, urine, sputum and the like), cells from amniotic fluid, cells from maternal blood (e.g., fetal cells), cells from testis and ovary, and the like.

[0058] As used in the disclosure, the term “biomolecule” or “biological molecule” refers to any molecule that is substantially of biological origin and encompasses proteins, peptides, and nucleic acids.

[0059] As used in the disclosure, the term "cleavable linker" refers to a linker that includes at least one bond that is cleavable under chemical or physical conditions, such as a bond that issensitive to temperature, light exposure, photon absorption, electro-chemical, pH change, acid, base, oxidation, metabolism, biochemistry or enzymatic action.

[0060] The methods and compositions provided herein are based at least in part on the inventors’ development of a highly sensitive and multiplexed in situ protein analysis approach that uses a cleavable labeled tyramide (CLT) comprising Formula I and / or a cleavable labeled styramide (CLST) comprising Formula IV, and which have the potential to quantify numerous different proteins and / or nucleic acids in individual cells of intact tissues at the optical resolution. As described herein, this development provides for in situ analysis of proteins, nucleic acids, and other biomolecules in intact tissues with single-molecule sensitivity.

[0061] Accordingly, in a first aspect, provided herein is a cleavable detectably-labeled tyramide / styramide. In certain embodiments, a detectable label such as a fluorophore is tethered to tyramide via a cleavable linker. Preferably, the cleavable linker is a chemically cleavable linker. As described herein, to enable signal removal (e.g., fluorescent signal) after protein staining, the cleavable detectably labeled tyramide / styramide preferably comprises a fluorophore tethered to tyramide / styramide through a chemically cleavable linker. An important aspect of the technology of this disclosure is efficient cleavage of the detectable label in a cellular environment while maintaining protein antigenicity. Additionally, it is preferred that the linker is small enough to permit recognition of CLT / CLST by horseradish peroxidase (HRP) and to avoid compromised diffusion of a short-lived tyramide / styramide radical. In some embodiments, the cleavable linker comprises the structure of Formula III, wherein R comprises a detectable marker and T comprises ty rami de / sty rami de :Formula III.

[0062] Other cleavable linkers appropriate for use in a CLT / CLST of this disclosure include, structures cleaved by enzymes, nucleophiles, electrophiles, reducing reagents, oxidizing reagents, photo-irradiation, metal catalysis, and the like. Further examples of suitable linkers and cleavage mechanisms are described by Milton et al. (U. S. Patent No. 7,414,116) and by Leriche et al.(Bioorg. Med. Chem., 2012, 20:571-582), which are incorporated herein by reference in their entirety. The linker may be cleavable using a variety of approaches including the addition of a chemical agent, irradiation with one or more wavelengths of light, enzymatic reaction and the like.

[0063] In some embodiments, a cleavable detectably-labeled tyramide is tyramide-N -, having the following chemical structure, Formula (I):wherein R is a detectable marker.

[0064] In some embodiments, the cleavable detectably-labeled tyramide is tyramide-Na-Cy5 ofFormula II:

[0065] The tyramide-N3-Cy5 of Formula II was designed and synthesized (FIG. IB) by tethering fluorophore Cy5 to tyramide through an azide-based cleavable linker. The synthesis and characterization of tyramide-N3-Cy5 is described in Example 1.

[0066] In some embodiments, a cleavable detectably-labeled styramide (CLST) comprising the compound of Formula (IV), wherein R is a detectable marker.Formula (IV).

[0067] In some embodiments, the cleavable detectably-labeled styramide is styramide-N3-Cy5 of Formula V:

[0068] In some embodiments, the cleavable detectably-labeled styramide comprises a molecule having Formula (VI):Linker-TAG

[0069] In some embodiments, X is a hydrogen. Linker is a cleavable linker having the structure of Formula III, and TAG is a detectable marker.

[0070] In some embodiments, each of the groups Rl, R2, R3, R4, R5, R6, and R7 can be one of hydroxyl group, H, alkyl, alkenyl, alkynyl, halogen, carboxy, alkoxy, aryloxy, thiol, alkylthiol, arylthiol, azido, nitro, nitroso, cyano, amino, hydroxy, phosphonyl, sulfonyl, carbonyl, boronyl, aryl or heteroaryl group. In some embodiments, Rl, R2, R3, R4, R5, R6, and R7 are the same. In some embodiments, one or more of the Rl, R2, R3, R4, R5, R6, and R7 are different from the others.

[0071] In some embodiments, the cleavable detectably-labeled styramide comprises a molecule having Formula (VII):

[0072] In some embodiments, X is a hydrogen. Linker is a cleavable linker having the structure of Formula III, and TAG is a detectable marker.

[0073] In some embodiments, each of the groups Rl, R2, R3, R4, R5, R6, R7, R8, R9, and R10 can be one of hydroxyl group, H, alkyl, alkenyl, alkynyl, halogen, carboxy, alkoxy, aryloxy, thiol, alkylthiol, arylthiol, azido, nitro, nitroso, cyano, amino, hydroxy, phosphonyl, sulfonyl, carbonyl, boronyl, aryl or heteroaryl group. In some embodiments, Rl, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are the same. In some embodiments, one or more of the Rl, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are different from the others.

[0074] In some embodiments, the cleavable detectably-labeled styramide comprises a molecule having Formula (VIII):

[0075] In some embodiments, X is a hydrogen. Linker is a cleavable linker having the structure of Formula III, and TAG is a detectable marker.

[0076] In some embodiments, each of the groups Rl, R2, R3, R4, R5, R6, R7, R8, R9, and RIO can be one of H, alkyl, alkenyl, alkynyl, halogen, carboxy, alkoxy, aryloxy, thiol, alkylthiol, arylthiol, azido, nitro, nitroso, cyano, amino, hydroxy, phosphonyl, sulfonyl, carbonyl, boronyl, aryl or heteroaryl group. In some embodiments, Rl, R2, R3, R4, R5, R6, R7, R8, R9, and RIO are the same. In some embodiments, one or more of the Rl, R2, R3, R4, R5, R6, R7, R8, R9, and RIO are different from the others.

[0077] Any appropriate detectable label can be used to produce a cleavable detectably-labeled tyramide or styramide. In some embodiments, the detectable label of the cleavable detectably- labeled tyramide or styramide is a fluorophore. In such cases, the cleavable detectably-labeled tyramide is cleavable fluorescent tyramide (CFT) and the cleavable detectably-labeled styramide is cleavable fluorescent styramide (CFST). Fluorophores useful in the methods of this disclosure include, without limitation, Cy5, TAMRA (labeled with tetramethylrhodamine or “TMR”), ALEXA FLUOR™ 594, and ATTO 647N and ATTO 700 fluorophores (ATTO-TEC, Germany). Other fluorophores appropriate for use according to the methods provided herein include, without limitation, quantum dots, ALEXA FLUOR™ 350, ALEXA FLUOR™ 532, ALEXA FLUOR™ 546, ALEXA FLUOR™ 568, ALEXA FLUOR™ 647, BODIPY 493 / 503, BODIPY FL, BODIPY R6G, BODIPY 530 / 550, BODIPY TMR, BODIPY 558 / 568, BODIPY 558 / 568, BODIPY 564 / 570, BODIPY 576 / 589, BODIPY 581 / 591, BODIPY 630 / 650, BODIPY 650 / 665, Cascade Blue, Cascade Yellow, Dansyl, lissamine rhodamine B, Marina Blue, Oregon Green 488, Oregon Green 514, Pacific Blue, rhodamine 6G, rhodamine green, rhodamine red, tetramethyl rhodamine, DYLIGHT™ DYES (e g., DYLIGHT™ 405, DYLIGHT™ 488, DYLIGHT™ 549, DYLIGHT™ 594, DYLIGHT™ 633, DYLIGHT™ 649, DYLIGHT™ 680, DYLIGHT™ 750, DYLIGHT™ 800 and the like), Texas Red, and Cy2, Cy3.5, Cy5.5, and Cy7, and sulfonated Cy2, Cy3.5, Cy5, Cy5.5, and Cy7. In addition to the use of fluorophores as a detectable moiety, other labels such asluminescent agents (e.g., chemiluminescent agents), fluorescent proteins, and radioisotopes can also be used as detection tags.

[0078] In another aspect, provided herein is a method for multiplexed in situ analysis of biomolecules in a tissue. As used herein, the term “multiplexed” refers to the detection of multiple signals (e.g., two or more signals), such as, for example, analytes, fluorescent signals, analog or digital signals, that are combined into one signal over a shared medium. The term encompasses the detection of multiple signals simultaneously in a single sample or single reaction vessel, as well as the combining of images of multiple signals to obtain one image that reflects the combination.

[0079] Referring to FIGs. 1A and C, the method comprises three steps in each analysis cycle. First, for analysis of a protein in a tissue, the tissue is contacted with a horseradish peroxidase (HRP)-conjugated antibody configured to bind specifically to the protein target. For analysis of nucleic acids in a tissue, the tissue is contacted with a HRP-conjugated oligonucleotide probe configured to hybridize to the nucleic acid target. In some embodiments, the HRP-conjugated targeting agent is configured to bind directly to the target biomolecule of interest. In some embodiments, the HRP-conjugated targeting agent binds to an intermediate, e.g., binds to a primary antibody or a primary oligonucleotide that binds directly to or hybridizes directly to the target biomolecule.

[0080] The tissue is also contacted with a detectably-labeled, cleavable tyramide as shown in FIG. 1A or a detectably-labeled, cleavable styramide, as shown in FIG. 1C. HRP catalyzes the coupling reaction between the cleavable tyramide / cleavable styramide and tyrosine residues on an endogenous protein target in close proximity, and produce fluorescent signals in close proximity to the target protein. In the second step, fluorescence images are captured to generate quantitative protein expression profiles. Finally, detectable labels attached to the cleavable tyramide or cleavable styramide are chemically cleaved in step that simultaneously deactivates HRP, which allows for initiation of the next analysis cycle. Through reiterative cycles of target staining, fluorescence imaging, fluorophore cleavage, and HRP deactivation, a large number of different target biomolecules with a wide range of expression levels can be quantified in single cells of intact tissues in situ.

[0081] In exemplary embodiments, the method comprises (a) contacting the tissue with a plurality of horseradish peroxidase (HRP)-conjugated targeting agents that are configured to specifically bind or hybridize to the target biomolecule in the contacted tissue, wherein the secondcontacting step occurs under conditions that promote binding or hybridization of the targeting agents to the target biomolecule; (b) contacting the tissue with the cleavable detectably-labeled tyramide (CLT) compound of Formula I / or the cleavable detectably-labeled styramide (CLST) compound of Formula IV, under conditions that promote conjugation of the cleavable labeled tyramide / styramide to the target biomolecule; (c) imaging the tissue thereby detecting the detectable marker; (d) contacting the tissue sample with a composition comprising 1,3,5-Triaza- 7-phosphaadamantane (PTA) and tris(2-carboxyethyl)phosphine (TCEP) at about 40°C for about 30 minutes; and (e) repeating steps (a) - (d), as necessary, depending on the number of biomarkers to be detected.

[0082] The targeting agent will vary depending on the type of target biomolecule. In some cases, the target biomolecule is a protein or peptide. In such cases, the targeting agent will be an antibody that specifically binds to the target protein or peptide. For example, if the target biomolecule is protein Histone deacetylase 2 (HDAC2), the target agents comprise anti-HDAC2 antibodies conjugated to HRP. Antibodies suitable for the methods include, without limitation, polyclonal antibodies, monoclonal antibodies, and antigen-binding fragments thereof. HRP- conjugated antibodies can be used to detect other target biomolecules such as lipids and metabolites.

[0083] In other cases, the target biomolecule is a nucleic acid (e.g., DNA, RNA). In such cases, the targeting agent will be a HRP-conjugated oligonucleotide having sequence complementary to the target nucleic acid sequence. Under appropriate conditions, the HRP -oligonucleotide will hybridize to the target nucleic acid sequence. In some cases, multiple cycles of the method are performed to detect multiple target biomolecules using targeting agents that are HRP-conjugated antibodies, HRP-conjugated oligonucleotides, or a combination thereof.

[0084] In some cases, the target biomolecule is a carbohydrate. In such cases, the targeting agent can be a HRP-conjugated lectin that is capable of binding carbohydrate. As used herein, the term “lectin” refers to a protein or glycoprotein that binds to specific carbohydrate structures to form a lectin-carbohydrate complex. The term encompasses lectins derived from animal and plant sources, and which bind carbohydrates by affinity. The term “lectin” as used herein also encompasses glycoproteins and proteins not normally termed lectins but which immunologically bind carbohydrates, such as antibodies, e.g., monoclonal antibodies. Since lectins bind selectively to some but not all carbohydrates (e.g., monosaccharides, such as mannose, GleNAc, gelatose, a-fructose or sialic acid) to different degrees, it will be understood that the type of lectin conjugated to HRP will vary depending on the target carbohydrate of interest.

[0085] Any appropriate method of preparing antibody-horseradish peroxidase conjugates can be used. Exemplary protocols for preparation of an HRP antibody conjugate are known in the art. By way of non-limiting example, HRP can be activated for conjugation by treatment with a 100- fold molar excess of a bifunctional PEG linker having a maleimide group and an active ester group. Antibodies to a protein of interest can be prepared for conjugation by introducing thiols using, for example, DTT. A thiolated antibody can be contacted to a molar excess of HRP comprising a bifunctional PEG linker for conjugation.

[0086] Likewise, methods of preparing an oligonucleotide probe conjugated to HRP are well known in the art and can be commercially obtained.

[0087] In some cases, the HRP-conjugated detection agent (e.g., antibody, oligonucleotide) and cleavable detectably labeled tyramide / styramide are contacted in the presence of a tyramide / styramide signal amplification buffer. In some cases, the amplification buffer comprises an aqueous phosphate-buffered, borate-buffered, or other buffered solution to which low concentrations of hydrogen peroxide are added. In some cases, the amplification buffer comprises 0.0015% H2O2 and 0.1% triton X-100 in 0.1 M boric acid, pH = 8.5. Commercial tyramide / styramide signal amplification buffers are available from several manufacturers including, for example, PerkinElmer, ThermoFisher, and Biotium.

[0088] In some embodiments, the signal from the detectable marker is removed in a "removing step." In some embodiments, the removing step comprises chemically cleaving the detectable label. Any appropriate means of removing a detectable signal or detectable label (e.g., a fluorophore) can be used according to the methods provided herein. Methods of removal can include without limitation one or more of photobleaching, chemical deactivation, chemical cleavage of the fluorophores (see the Examples below), enzymatic cleavage of the fluorophores, DNA / RNA strand displacement, chemical or heat denaturing of an intermediate fluorescent oligonucleotide, and the like. Since photobleaching can be a time-consuming step, in some cases the methods provided herein comprise efficiently removing fluorescence signals by chemical deactivation or chemical or enzymatic cleavage of detectable labels.

[0089] In some cases, the methods provided herein comprise chemical inactivation of fluorophores. For example, fluorophores can be inactivated by oxidation. Protocols for oxidation of dyes with hydrogen peroxide, which can be catalyzed using either acidic or basic conditions, orreactive oxygen species (ROS) are known to those practitioners in the art for changing the fluorescent properties of dyes and fluorescent proteins.

[0090] In some embodiments, the detectable marker is removed by chemical cleavage of the linker joining the tyramide / styramide and the detectable marker. In some embodiments, the linker is cleaved by contacting the sample with tris(2-carboxyethyl)phosphine (TCEP), and 1,3,5-Triaza- 7-phosphaadamantane (PTA), either as separate components or as a composition. In some embodiments, the contacted sample is incubated at a temperature of about 30°C, 31°, C32°, 33°C, 34°C, 35°C, 36°C, C37°C, 38°C, 39°C, C40°C, 41°C, 42°C, C43°, 44°C, 45°C, 46°C, 47°C, C48°C, 49°C or about 50°C. The time of incubation is about 10 to about 120 minutes, 20 to about 90 minutes, 30 to about 60 minutes, or about 30 minutes. In some embodiments, the sample is washed prior to the next cycle.

[0091] When fluorescently labeled tyramide or fluorescently labeled styramide is used, fluorescence photomicroscopy can be used to detect and record the results of consecutive in situ analysis using routine methods known in the art. Alternatively, digital (computer implemented) fluorescence microscopy with image-processing capability may be used. Two well-known systems for imaging FISH of chromosomes having multiple colored labels bound thereto include multiplex-FISH (M-FISH) and spectral karyotyping (SKY). See Schrock et al. (1996) Science 273:494; Roberts et al. (1999) Genes Chrom. Cancer 25:241; Fransz et al. (2002) Proc. Natl. Acad. Sci. USA 99: 14584; Bayani et al. (2004) Curr. Protocol. Cell Biol. 22.5.1-22.5.25; Danilova et al. (2008) Chromosoma 117:345; U.S. Pat. No. 6,066,459; and FISH TAG™ DNA Multicolor Kit instructions (Molecular probes) for a review of methods for painting chromosomes and detecting painted chromosomes.

[0092] To minimize issues of autofluorescence or background signal, oligonucleotide targeting agents can be designed to hybridize to a target nucleic acid at multiple places on the target nucleic acid sequence. Thus, an increased number of oligonucleotides will hybridize to each target nucleic acid sequence (e.g., transcript) to enhance signal to noise ratio. As used herein, the terms “binding,” “to bind,” “binds,” “bound,” or any derivation thereof refers to any stable, rather than transient, chemical bond between two or more molecules, including, but not limited to, covalent bonding, ionic bonding, and hydrogen bonding. The term “binding” encompasses interactions between polypeptides, for example, an antibody and its epitope on a target protein. The term also encompasses interactions between a nucleic acid molecule and another entity such as a nucleic acid or probe element. Specifically, binding, in certain embodiments, includes the hybridization ofnucleic acids. In some cases, the methods further comprise a blocking step to reduce background signal. The term “blocking” as used herein refers to treatment of a sample with a composition that prevents the non-specific binding of the target substance to the sample. Typically a blocking composition comprises a protein, such as casein or albumin, and may additionally comprise surfactants. The function of the blocking protein is to bind to the sample to prevent the non-specific binding of assay reagents.

[0093] In some cases, the method further comprises a washing step. For example, the method can further comprise washing to remove unhybridized targeting agents and non-specifically hybridized targeting agents prior to the addition of CLT / CLST to the sample (e.g., prior to the tyramide-HRP reaction), and prior to visualization. In some embodiments, the methods comprises a washing step after cleaving the detectable label and prior to the next cycle including the addition of a next targeting agent.

[0094] In some embodiments, the methods comprise a stripping step. As used herein, the term “stripping” refers to the process of interfering with the non-covalent binding between a target biomolecule in a sample and a horseradish peroxidase (HRP)-conjugated targeting agent such that significant amounts of targeting agent is eluted or “stripped” away from the in situ sample. The term “stripping” encompasses using heat, a buffer, denaturing agent, detergent, temperature condition, pH condition, osmolarity agent, or any combination thereof. Non-limiting examples of stripping include boiling a sample or subjecting a sample to a boiling solution, subjecting a sample to a very low pH (e.g. pH 2) or high pH (e g. pH 10), and / or subjecting a sample to a denaturing agent or detergent, such as, e.g., subjecting a sample to SDS, a glycine buffer, glycine SDS, and / or boiling a sample in citrate buffer. Heat-induced stripping may optionally be accomplished by microwaving a sample or subjecting a sample to solution which has recently been microwaved or otherwise brought to its boiling point. For example, heat-induced stripping encompasses subjecting a sample to a 100° C condition for at least about 1 minute, 5 minutes, 10 minutes, 20 minutes, or greater. Stripping may optionally be accomplished using a combination of heat- induced stripping and another agent or condition, such as, e.g., a buffer, pH condition, osmolarity agent, detergent, denaturing agent, or any combination thereof..

[0095] The methods of this disclosure can be performed using a tissue sample obtained from any biological entity. The term “biological entity” as used herein means any independent organism or thing, alive or dead, containing genetic material (e.g., nucleic acid) that is capable of replicating either alone or with the assistance of another organism or cell. Sources for nucleic acid-containingbiological entities include, without limitation, an organism or organisms including a cell or cells, bacteria, yeast, fungi, algae, viruses, or a sample thereof. Specifically, an organism of the current disclosure includes bacteria, algae, viruses, fungi, and mammals (e.g., humans, non-human mammals). The methods and compositions described herein can be performed using a variety of biological or clinical samples comprising cells that are in any (or all) stage(s) of the cell cycle (e.g., mitosis, meiosis, interphase, GO, Gl, S and / or G2). As used herein, the term “sample” include all types of cell culture, animal or plant tissue, peripheral blood lymphocytes, buccal smears, touch preparations prepared from uncultured primary tumors, cancer cells, bone marrow, cells obtained from biopsy or cells in bodily fluids (e.g., blood, urine, sputum and the like), cells from amniotic fluid, cells from maternal blood (e.g., fetal cells), cells from testis and ovary, and the like. In some cases, samples are obtained by swabbing, washing, or otherwise collecting biological material from a non-biological object such as a medical device, medical instrument, handrail, door knob, etc. Samples are prepared for assays of this disclosure using conventional techniques, which typically depend on the source from which a sample or specimen is taken. These examples are not to be construed as limiting the sample types applicable to the methods and / or compositions described herein.

[0096] In some cases, the methods provided herein comprise a cell or tissue fixation step. For example, the cells of a biological sample (e.g., tissue sample) can be fixed (e.g., using formalin, formaldehyde, or paraformaldehyde fixation techniques known to one of ordinary skill in the art). In some cases, the tissue is formalin-fixed and paraffin-embedded (FFPE). Any fixative that does not affect antibody binding or nucleic acid hybridization can be utilized in according to the methods provided herein. In other cases, the methods are performed on unfixed (“fresh”) tissue samples.

[0097] As described herein, the methods of the present invention provide for multiplexed in situ analysis of biomolecules in a tissue. Through consecutive cycles of targeting agent binding / hybridization, fluorescence imaging, and signal removal, different biomolecule species can be identified as fluorescent spots with unique color sequences. In some embodiments, the CLT has different cycles, which are used in conjunction with different targeting agents, comprise different labels. For example, in a first cycle, a first targeting agent is hybridized to a first target biomolecule, and a first CTL comprising a first detectable label is used. In a subsequent cycle, an second targeting agent is hybridized to a second target biomolecule, and a second CTL comprising a second detectable label is used.

[0098] Tn some embodiments, the CLST is of different cycles, which are used in conjunction with different targeting agents, comprise different labels. For example, in a first cycle, a first targeting agent is hybridized to a first target biomolecule, and a first CLST comprising a first detectable label is used. In a subsequent cycle, an second targeting agent is hybridized to a second target biomolecule, and a second CLST comprising a second detectable label is used.

[0099] As used herein, the term “biomolecule” or “biological molecule” refers to any molecule that is substantially of biological origin and encompasses proteins, peptides, and nucleic acids. Such molecules may include non-naturally occurring components that mimic a naturally occurring component, e.g., a non-naturally occurring amino acid. The terms “polypeptide,” “peptide” and “protein” are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers, those containing modified residues, and non-naturally occurring amino acid polymer. As used herein, the terms “nucleic acid” or “oligonucleotide” refer to and encompass any physical string or collection of monomer units (e.g., nucleotides) that can connect to form a string of nucleotides, including a polymer of nucleotides (e.g., a typical DNA or RNA polymer), peptide nucleic acids (PNAs), modified oligonucleotides (e.g., oligonucleotides comprising nucleotides that are not typical to biological RNA or DNA, such as 2'-O-methylated oligonucleotides), and the like. The nucleotides of the nucleic acid can be deoxyribonucleotides, ribonucleotides or nucleotide analogs, and can be natural or non-natural, and can be unsubstituted, unmodified, substituted or modified. The nucleotides can be linked by phosphodiester bonds, or by phosphorothioate linkages, methylphosphonate linkages, boranophosphate linkages, or the like. The nucleic acid can additionally comprise non-nucleotide elements such as labels, quenchers, blocking groups, or the like. The nucleic acid can be single-stranded or double-stranded.

[0100] As used herein, the terms “nucleic acid of interest,” and “target nucleic acid” include a nucleic acid originating from one or more biological entities within a sample. The target nucleic acid of interest to be detected in a sample can be a sequence or a subsequence from DNA, such as nuclear or mitochondrial DNA, or cDNA that is reverse transcribed from RNA in the sample. The sequence of interest can also be from RNA, such as mRNA, rRNA, tRNA, miRNA, siRNAs, antisense RNAs, or long noncoding RNAs. More generally, the sequences of interest can be selected from any combination of sequences or subsequences in the genome or transcriptome of a species or an environment. In some cases, a defined set of targeting agents are oligonucleotideprobes that are designed to hybridize to the plurality of sequences that would be expected in a sample, for example a genome or transcriptome, or a smaller set when the sequences are known and well-characterized, such as from an artificial source.

[0101] Oligonucleotide probes useful for the methods provided herein are of any length sufficient to permit probe penetration and to optimize hybridization of probes for in situ analysis according to the methods of this disclosure. Preferably, probe length is about 20 bases to about 500 bases. As probe length increases, so increases the number of binding sites that can be incorporated into a given probe for hybridization to the probe of the following cycle as well as the signal to noise ratio. However, longer than 500 bases, the probes may not efficiently penetrate the cellular membrane. Preferably, the oligonucleotide probes have a probe length between 20 and 500 nucleotides, 20 and 250, 50 and 250, 150 and 250 nucleotides, 20 and 150, or 50 and 150 nucleotides, inclusive.

[0102] The terms “hybridize” and “hybridization” as used herein refer to the association of two nucleic acids to form a stable duplex. Nucleic acids hybridize due to a variety of well characterized physico-chemical forces, such as hydrogen bonding, solvent exclusion, base stacking and the like. An extensive guide to the hybridization of nucleic acids is found in Tijssen (1993) Laboratory Techniques in Biochemistry and Molecular Biology-Hybridization with Nucleic Acid Probes, part I chapter 2, “Overview of principles of hybridization and the strategy of nucleic acid probe assays” (Elsevier, N.Y.). One of skill in the art will understand that “hybridization” as used herein does not require a precise base-for-base complementarity. That is, a duplex can form, between two nucleic acids that contained mismatched base pairs. The conditions under which nucleic acids that are perfectly complementary or that contain mismatched base pairs will hybridize to form a duplex are well known in the art and are described, for example, in MOLECULAR CLONING: A LABORATORY MANUAL, 3rded., Sambrook et al., eds., Cold Spring Harbor Press, Cold Spring Harbor (2001) at Chapter 10, which is herein incorporated by reference. As used herein, the term “complementary” refers to a nucleic acid that forms a stable duplex with its “complement”. For example, nucleotide sequences that are complementary to each other have mismatches at less than 20% of the bases, at less than about 10% of the bases, preferably at less than about 5% of the bases, and more preferably have no mismatches.

[0103] Kits

[0104] In another aspect, provided herein is a kit comprising reagents for performing multiplexed in situ analysis of biomolecules in a tissue. In one embodiment, preferably, the kitcomprises a cleavable detectably-labeled tyramide of Formula I or Formula II, and a written insert component comprising instructions for performing multiplexed in situ analysis of target biomolecules according to the methods provided herein. In one embodiment, preferably, the kit comprises a cleavable detectably-labeled styramide of Formula IV or Formula V, and a written insert component comprising instructions for performing multiplexed in situ analysis of target biomolecules according to the methods provided herein.

[0105] In some embodiments, the kit further comprises a one or more HRP-conjugated targeting agents configured to bind or hybridize to a target biomolecule. As described herein, the targeting agents can be synthetic DNA oligonucleotide probes, polyclonal antibodies, monoclonal antibodies, antigen-binding fragments of an antibody, or some combination thereof. In some embodiments, the plurality of HRP-conjugated targeting agents comprises HRP-conjugated synthetic DNA oligonucleotide probes. In some embodiments, the plurality of HRP-conjugated targeting agents comprises HRP-conjugated polyclonal or monoclonal antibodies, or antigenbinding fragments thereof. In some embodiments, the kit further comprises an amplification reaction buffer, a blocking reagent, and / or a hydrogen peroxide additive.

[0106] In some embodiments, the detectable maker includes, without limitation, fluorophores, luminescent agents (e.g., chemiluminescent agents), fluorescent proteins, and radioisotopes. By way of example, detectable markers include Cy5, sulfonated cy5, TAMRA (labeled with tetramethylrhodamine or “TMR”), ALEXA FLUOR™ 594, and ATTO 647N and ATTO 700 fluorophores (ATTO-TEC, Germany). Other fluorophores appropriate for use according to the compositions and methods provided herein include, without limitation, quantum dots, ALEXA FLUOR™ 350, ALEXA FLUOR™ 532, ALEXA FLUOR™ 546, ALEXA FLUOR™ 568, ALEXA FLUOR™ 647, BODIPY 493 / 503, BODIPY FL, BODIPY R6G, BODIPY 530 / 550, BODIPY TMR, BODIPY 558 / 568, BODIPY 558 / 568, BODIPY 564 / 570, BODIPY 576 / 589, BODIPY 581 / 591, BODIPY 630 / 650, BODIPY 650 / 665, Cascade Blue, Cascade Yellow, Dansyl, lissamine rhodamine B, Marina Blue, Oregon Green 488, Oregon Green 514, Pacific Blue, rhodamine 6G, rhodamine green, rhodamine red, tetramethyl rhodamine, DYLIGHT™ DYES (e g., DYLIGHT™ 405, DYLIGHT™ 488, DYLIGHT™ 549, DYLIGHT™ 594, DYLIGHT™ 633, DYLIGHT™ 649, DYLIGHT™ 680, DYLIGHT™ 750, DYLIGHT™ 800 and the like), Texas Red, and Cy2, Cy3.5, Cy5.5, and Cy7, and sulfonated Cy2, Cy3.5, Cy5, Cy5.5, and Cy7. In some embodiments, the detectable marker is a sulfonated Cy 5, and in some embodiments, there is provided a cleavable detectably-labeled tyramide (CLT) comprising the compound of Formula(II). In some embodiments, there is provided a cleavable detectably-labeled styramide (CLST) comprising the compound of Formula (V)

[0107] In some embodiments, the kit includes instructions for employing the kit components as well the use of any other reagent not included in the kit. Instructions may include variations that can be implemented. In some embodiments, the kit further comprises tris(2- carboxyethyl)phosphine (TCEP) and l,3,5-Triaza-7-phosphaadamantane (PTA) either as separate components or as a composition. In such cases, the written instruction component further comprises instructions for removing the detectable label from the detectably-labeled tyramide using the TCEP / PTA.

[0108] Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference for the purpose of describing and disclosing the chemicals, cell lines, vectors, animals, instruments, statistical analysis and methodologies which are reported in the publications which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

[0109] Various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below find experimental support in the following examples which, together with the above descriptions, illustrate some embodiments of the invention in a non-limiting fashion.EXAMPLESExample 1: Multiplexed in situ protein profiling with high-performance cleavable fluorescent tyramide.

[0110] Abstract: Understanding the composition, function and regulation of complex cellular systems require tools that quantify the expression of multiple proteins at their native cellular context. Here, the inventors report a highly sensitive and accurate protein in situ profiling approach using off-the-shelf antibodies and cleavable fluorescent tyramide (CFT). In each cycle of this method, protein targets are stained with horseradish peroxidase (HRP) conjugated antibodies and CFT. Subsequently, the fluorophores are efficiently cleaved by mild chemical reagents, whichsimultaneously deactivate HRP. Through reiterative cycles of protein staining, fluorescence imaging, fluorophore cleavage, and HRP deactivation, multiplexed protein quantification in single cells in situ can be achieved. The inventors designed and synthesized the high-performance CFT, and demonstrated that over 95% of the staining signals can be erased by mild chemical reagents while preserving the integrity of the epitopes on protein targets. Applying this method, the inventors explored the protein expression heterogeneity and correlation in a group of genetically identical cells. With the high signal removal efficiency, this approach also enables us to accurately profile proteins in formalin-fixed paraffin-embedded (FFPE) tissues in the order of low to high and also high to low expression levels.

[0111] Introduction: Highly multiplexed protein profiling in their native spatial contexts holds great promise to reveal the composition, regulation and interaction of the various cell types in complex cellular systems [1,2]. Protein microarray [3] and mass spectrometry [4] are well- established methods for proteomic analysis. However, as these approaches do not quantify proteins in their original cellular environment, the location information of the proteins are lost during analysis. Immunofluorescence is a powerful tool for in situ protein quantification. Nonetheless, due to the spectral overlap of the common fluorophores, immunofluorescence only allows a small number of varied proteins to be profiled on each specimen [5],

[0112] To allow multiplexed in situ protein analysis, several techniques [6-14] have been explored. In these approaches, the fluorophores or metal isotopes directly conjugated antibodies are applied as detections tags. Without further signal amplification, these approaches suffer from low detection sensitivity, which limits their applications for analysis of low expression proteins or studying highly autofluorescent specimen, such as formalin fixed, paraffin embedded (FFPE) tissues [7], Recently, some signal amplification methods have been developed for multiplexed protein imaging [15,16], However, these approaches require a chemical or oligonucleotide tag to be conjugated to primary antibodies. To prepare those tag conjugated primary antibodies can be time-consuming and expensive. More importantly, the bulky chemical or oligonucleotide tag can interfere with the binding affinity and specificity of the primary antibodies.

[0113] To enable highly sensitive and multiplexed protein imaging with off-the-shelf antibodies, our group developed a reiterative protein staining approach using cleavable fluorescent tyramide (CFT)

[0017] , The inventors demonstrated its sensitivity is improved by about two orders of magnitude compared with other existing methods. As a result, its imaging time is dramatically reduced, and the sample throughput is significantly enhanced. However, some non-ideal factorsstill exist. For example, the carbamate group in the first-generation CFT could potentially react with the nucleophiles in the cellular environment or during storage, which may lead to side reactions or short shelflife. Additionally, with tris(2-carboxyethyl)phosphine (TCEP) as the signal removal reagent, the first-generation CFT requires 65°C to remove -95% of the staining signals. Nevertheless, this relatively high reaction temperature could damage the integrity of the epitopes

[0017] .

[0114] Here, the inventors report a highly sensitive and multiplexed in situ protein analysis method using high-performance CFT. In this approach, protein targets are recognized by antibodies conjugated with horseradish peroxidase (HRP) and then stained with CFT. Without the carbamate group in this newly designed CFT, it avoids the potential side reactions with the cellular nucleophiles. Additionally, over 95% the staining signals can be efficiently removed using 1,3,5- Triaza-7-phosphaadamantane (PTA) and TCEP at 40°C. And simultaneously, HRP is also effectively deactivated under this mild condition. Through reiterative cycles of target staining, fluorescence imaging, signal erasing and HRP quenching, the inventors demonstrated at least 10 reiterative immunofluorescence cycles can be successfully carried out in cultured cells. With the generated multiplexed single-cell in situ protein profiling data, the inventors explored the protein expression heterogeneity and correlation in a population of genetically identical cells. The inventors also showed the significantly improved signal removal efficiency of our approach enables the accurate quantification of multiple proteins in the order of low to high and also high to low expression levels in FFPE tissues.

[0115] 1. Materials and Methods

[0116] 1.1 General information

[0117] Chemicals and solvents were purchased from Sigma-Aldrich, and were used directly without further purification. Bioreagents were purchased from Invitrogen, unless otherwise noted.

[0118] 1.2 Synthesis of tyramide-N s-Cy5

[0119] Cy5-N3 acid (8.3 pmol), prepared according to the literature

[0018] , N,N,N',N'~ Tetramethyl-O-(N-succinimidyl)uronium tetrafluoroborate (TSTU) (12.5 mg, 41.5 pmol) and ;V,A'-diisopropylethylamine (DIPEA) (7.3 pL, 41.5 pmol) was mixed in anhydrous DMF (300 pL) and stirred at room temperature. The complete transformation of Cy5-N.3 acid into Cy5-Na NHS ester was observed via TLC (DCM:Methanol = 5: 1) after 30 minutes. Then, tyramine hydrochloride (6.23 mg, 41.5 pmol) and DIPEA (14.6 pL, 83.0 pmol) were added into the reaction mixture and stirred for 2 hours. The solvent was evaporated, and the solid residue was purified bypreparative TLC (DCM:Methanol = 5: 1) to obtain the product as dark blue solid. tyramide-N3-Cy5 was further purified by semi preparative reversed phase HPLC [HPLC gradient: A, 100% 0.1 M TEAA; B 100% MeCN; 0-2 min, 5% B (flow 2-5 ml / min); 2-10 min, 5-22% B (flow 5 ml / min); 10-15 min, 22-30% B (flow 5 ml / min); 15-20 min, 30-40% B (flow 5 ml / min); 20-25 min, 40- 50% B (flow 5 ml / min); 25-30 min, 50-60% B (flow 5 ml / min); 30-32 min, 60-70% B (flow 5 ml / min); 32-35 min, 70-95% B (flow 5 ml / min); 35-37 min, 95% B (flow 5 ml / min); 37-39 min, 95-5% B, (flow 5 ml / min); 39-42 min, 5% B (flow 5-2 ml / min)]. The fraction with retention time of 26.4 minutes was collected. After evaporating all the solvents, the residue was co-evaporated with methanol twice to obtain pure tyramide-N3-Cy5 as blue solid (3.53 mg, 3.10 pmol). 'H NMR [500 MHz MeOD]: 8.25 (2H, SO3H, t, J = 16.5 Hz), 7.90 (4H, Ar-H, m), 7.35-7.10 (5H, Ar-H, m), 6.95 (1H, Ar-H, m), 6.9 (2H, Ar-H, d, J= 10.5 Hz), 6.62-6.52 (3H, 2xAr-H and CH=, m), 6.27- 6.14 (2H, CH=, dd, J = 17 Hz, J= 8.0 Hz), 4.7 (1H, CH-N3, t, J = 8.0 Hz), 4.10-3.96 (4H, 2xCH2N, m), 3.90 (2H, OCH2, t, J= 9.0 Hz), 3.84-3.77 (3H, OCH2, Hb and CH2C(O), m), 3.65-3.60 (1H, OCH2, Ha, m), 3.53 (2H, CH2N, t, J = 7.5 Hz), 3.37 (2H, CH2N, t, J = 5.0 Hz), 3.29 (2H, CH2O, t, J = 5.0 Hz), 2.57 (2H, CH2N, t, J = 9.0 Hz), 2.13-2.01 (4H, CH2and CH2C(O), m), 1.65-1.52 (15H, 4XCH3and CH3, m), 1.33-1.24 (6H, 3xCH2, m). HRMS (ESI-, m / z) calculated for C57H71N8O13S2 [(M-2H) ’]: 1137.4529, found: 1137.4327.

[0120] 1.3 Deparaffinization and antigen retrieval of FFPE tonsil tissue.

[0121] An FFPE Tonsil tissue was heated at 60°C for 1 h before being deparaffmized in xylene 5 times, each for 4 minutes. Afterwards, the slide was immersed in 100% ethanol for 4 minutes twice, 95% ethanol for 4 minutes, 75% ethanol for 4 minutes then rinsed with DI water. Heat induced antigen retrieval (HIAR) was performed on the slide by using the microwave. The slide was immersed in antigen retrieval buffer (diluted 100 times from Abeam 100X Citrate Buffer pH 6.0 with DI water) and heated in the microwave for 2 minutes and 40 seconds at level 10 setting and then for 14 minutes at level 2 setting. After cooling down for 20 minutes, the slide was rinsed with DI water.

[0122] 1.4 Protein staining in FFPE tonsil tissue

[0123] To deactivate the endogenous peroxidase, the slide was incubated with 3% H2O2for 10 minutes at room temperature, followed by 3 times washes using IX PBT in PBS. Next, the slide was incubated with IX blocking buffer for 30 min at room temperature. Then, the slide was incubated with 5 pg / mL rabbit anti hnRNP K, HRP (Abeam; ab204456) in antibody blocking buffer for 1 h, and washed 3 times with IX PBT, each for 5 min. The slide was stained withtyramide-N3-Cy5 at the concentration of 10 nmol / mL in amplification buffer for 7 minutes at room temperature, then washed 3 times with IX PBT, each for 5 minutes. The stained tissue was incubated with GLOX buffer (10 mM Tris HC1 and 0.4% glucose in 2X saline-sodium citrate (SSC) buffer (30 mM trisodium citrate, 300 mM sodium chloride, pH = 7.0)) at room temperature for 1 min, and subsequently imaged in GLOX solution (1% catalase and 0.37 mg / mL glucose oxidase in GLOX buffer).

[0124] 1.5 Fluorophore cleavage and HRP deactivation.

[0125] The stained tissue was incubated with 100 mM l,3,5-Triaza-7-phosphaadamantane (PTA) and 100 mM tris(2-carboxyethyl)phosphine (TCEP) sequentially at 40°C, each for 30 minutes. After 5 min wash with PBT and IX PBS, each for 3 times, the tissue was imaged in GLOX solution.

[0126] 1.6 Effect of cleavage by PTA

[0127] After deparaffined and antigen retrieved, an FFPE tonsil tissue was incubated with 100 mM PTA overnight at 40°C. Then, the slide was washed 3 times with IX PBT, each for 5 min. Subsequently, the slide was incubated with 5 pg / mL rabbit anti ILF3, HRP (Abeam; ab206250) and stained with tyramide-N3-Cy5. In the control experiment, without PTA treatment in advance, another FFPE tonsil tissue was directly stained with rabbit anti ILF3, HRP (Abeam; ab206250) and tyramide-N3-Cy5.

[0128] 1. 7 Cell culture

[0129] HeLa CCL-2 cells (ATCC) were maintained in a humidified atmosphere with 5% CO2 at 37 °C in Dulbelcco’s modified Eagle’s Medium (DMEM), which was supplemented with 100 U / mL penicillin, 100 g / mL streptomycin and 10% fetal bovine serum. Cells plated on chambered coverglass (200 pL medium / chamber) (Thermo Fisher Scientific) were allowed to reach -60% confluency in 1 to 2 days.

[0130] 1.8 Cell fixation and permeabilization

[0131] Cultured HeLa cells were fixed with 4% formaldehyde (Polysciences) in IX phosphate buffered saline (PBS) (pH = 7.4) for 15 min at 37 °C. Subsequently, the cells were washed with IX PBS three times, each for 5 min. After permeabilized with PBT (0.1% Triton-X 100 in IX PBS) at room temperature for 10 min, cells were washed with IX PBS three times, each for 5 min.

[0132] 1.9 Immunofluorescence with CFT

[0133] To block endogenous peroxidase, fixed and permeabilized HeLa cells were incubated with 0.15% H2O2 in PBT for 10 min, and subsequently washed three times with IX PBS, each for5 min. Then, the cells were blocked with IX blocking buffer (0.1% (vol / vol) Triton X-100, 1% (wt / vol) bovine serum albumin and 10% (vol / vol) normal goat serum) for 1 h at room temperature. Subsequently, the cells were incubated with 5 pg / mL HRP conjugated primary antibodies in IX blocking buffer for 1 h, followed by 3 times wash with PBT, each for 5 min. Then, the cells were incubated with tyramide-N3-Cy5 at the concentration of 10 nmol / mL in amplification buffer (0.1 M Boric acid, pH = 8.5) for 7 min. Afterwards, the cells were washed quickly with PBT twice, and then washed with PBT again for 3 times, each for 5 min. The stained cells were incubated with GLOX buffer (10 mM Tris HC1 and 0.4% glucose in 2X saline-sodium citrate (SSC) buffer (30 mM trisodium citrate, 300 mM sodium chloride, pH = 7.0)) at room temperature for 1 min, and subsequently imaged in GLOX solution (1% catalase and 0.37 mg / mL glucose oxidase in GLOX buffer). The primary antibodies used in this work include rabbit anti-HMGBl, HRP (Thermo Fisher Scientific; PA5-22722), rabbit anti-HDAC2, HRP (Abeam; ab 195851), rabbit anti-TDP43, HRP (Abeam; abl93850), rabbit anti-PABPNl, HRP (Abeam; ab207515), rabbit anti-hnRNP Al, HRP (Abeam; ab 198535), mouse anti-Nucleolin, HRP (Abeam; ab 198492), rabbit anti -Histone H4 (acetyl K16) , HRP (Abeam; ab200859), mouse anti-hnRNP K, HRP (Abeam; ab204456), rabbit anti-ILF3, HRP (Abeam; ab206250) and mouse anti-Nucleophosmin, HRP (Abeam; ab202579).

[0134] 1. lOMultiplexed protein imaging in cells.

[0135] Fixed and blocked HeLa cells were incubated with HRP conjugated antibodies at the concentration of 5 pg / mL for 1 h at room temperature, and subsequently stained with tyramide- N3-Cy5. Afterwards, the stained cells were imaged and then incubated with 100 mM PTA and 100 mM TCEP sequentially at 40°C, each for 30 minutes. The cells were imaged again, followed by the next cycle of immunofluorescence. The sequentially applied antibodies include rabbit anti- HMGBl, HRP (Thermo Fisher Scientific; PA5-22722), rabbit anti-HDAC2, HRP (Abeam; abl95851), rabbit anti-TDP43, HRP (Abeam; abl93850), rabbit anti-PABPNl, HRP (Abeam; ab207515), rabbit anti-hnRNP Al, HRP (Abeam; abl98535), mouse anti-Nucleolin, HRP (Abeam; ab 198492), rabbit anti-Histone H4, HRP (acetyl KI 6) (Abeam; ab200859), mouse anti- hnRNP K, HRP (Abeam; ab204456), rabbit anti-ILF3, HRP (Abeam; ab206250) and mouse anti- Nucleophosmin, HRP (Abeam; ab202579). In control experiments, fixed and blocked HeLa cells were incubated with HRP conjugated primary antibodies at the concentration of 5 pg / mL for 1 h at room temperature, and subsequently stained with Cy5-tyramide (PerkinElmer).

[0136] 1.11 Multiplexed protein imaging in FFPE tonsil tissue.

[0137] After deparaffinization and antigen retrieval, the endogenous peroxidase in FFPE tonsil tissues were blocked by 3% H2O2. Subsequently, the slide was incubated with HRP conjugated antibodies at the concentration of 5 pg / mL for 1 h at room temperature, and then stained with tyramide-N3-Cy5. Afterwards, the stained tissues were imaged and then incubated with 100 mM PTA and 100 mM TCEP sequentially at 40°C, each for 30 minutes. The tissues were imaged again, followed by the next cycle of immunofluorescence. The antibodies, rabbit anti-ILF3, HRP (Abeam; ab206250), mouse anti-Nucleophosmin, HRP (Abeam; ab202579) and mouse anti- hnRNP K, HRP (Abeam; ab204456), were applied in the forward and reverse orders on two different slides.

[0138] 1.12 Imaging and Data Analysis

[0139] The HeLa cells and FFPE tonsil tissues were imaged using a Nikon Ti-E epifluorescence microscope with a 20* objective, Chroma fdter 49009 and a CoolSNAP HQ2 camera. Image analysis was performed with NIS-Elements Imaging software.

[0140] 2. Results

[0141] 2.1 Platform design

[0142] In this multiplexed protein imaging approach, each staining cycle is composed of three major steps (Figure 1A). First, the protein of interest is recognized by over-the- shelf antibodies labeled with HRP, which catalyzes the coupling reaction between the tyramide in CFT and the tyrosine residues on the proteins proximal to the antibodies. Second, the specimen is imaged under a fluorescence microscope to generate quantitative single-cell in situ protein expression profiles. In the last step, the fluorophores tethered to tyramide are efficiently removed by chemical cleavage, and HRP is simultaneously deactivated. With continuous cycles of staining, imaging, cleavage and HRP deactivation, highly multiplexed and sensitive protein profiling can be achieved in single cells in situ.

[0143] 2.2. Design and synthesis of high performance CFT

[0144] To eliminate the potential side reactions with the cellular nucleophiles and also improve the shelf life, the high-performance CFT should avoid the carbamate group. Additionally, the linker tethering the fluorophore and tyramide must be cleaved efficiently under a mild condition by a bioorthogonal reaction. Our group recently has developed cleavable fluorescent oligonucleotide for comprehensive RNA and DNA in situ profiling

[0018] , The azide-based linker used in that method satisfies the two requirements for successful CFT. Therefore, that linker is applied to couple the fluorophore to tyramide in high performance CFT. Most tissues exhibitstronger autofluorescence in the green and yellow emission channels than in the red channel

[0019] , Thus, to minimize the impact of autofluorescence on the accurate protein analysis, the inventors applied Cy5 as the fluorophore in CFT under the current study.

[0145] To synthesize the designed tyramide-N3-Cy5 (Figure IB), Cy5 NHS ester was first coupled the azide-based linker, as previously reported in the literature. The generated product was subsequently converted into the NHS ester and conjugated with tyramine. The prepared CFT was purified by high performance liquid chromatography (HPLC) and characterized by nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry.

[0146] 2.3. Efficient fluorophore cleavage while preserving epitope integrity

[0147] One consideration for the success of the multiplexed protein imaging approach is to efficiently remove the staining signals without loss of protein antigeneity. In this way, the signal leftover generated in the previous cycles can be minimized, and other protein targets can still be successfully recognized by antibodies in the following immunofluorescence cycles. To assess the fluorophore cleavage efficiency of the high-performance CFT, the inventors stained protein ILF3 in a human tonsil FFPE tissue (Figure 2A). To facilitate the efficient signal removal in different microenvironment, the inventors applied the positively charged phosphine PTA in combination with the negatively charged phosphine TCEP to perform fluorophore cleavage. After incubating with PTA and TCEP at 40°C for 30 min, over 95% of the signals were removed (Figure 2B, C). Compared with the first-generation CFT, the reaction temperature of 65°C is required to achieve the similar cleavage efficiency. However, that high cleavage temperature leads to the partial loss of protein antigeneity. The results here suggest that the fluorophore in the high-performance CFT can be very efficiently removed under a relatively low cleavage temperature.

[0148] The inventors next investigated whether the epitope integrity is preserved under this cleavage condition. Previously, the inventors have shown that the TCEP treatment at this relatively low temperature does not result in loss of protein antigeneity [8], Thus, here the inventors evaluated the effects of the PTA incubation on the epitope integrity (Figure 3). After the PTA treatment overnight, protein ILF3 was stained in a human tonsil FFPE tissue. The generated staining patterns (Figure 3A, B) and signal intensities (Figure 3C) are consistent with the ones obtained without the PTA treatment. These results indicate that the antibody antigeneity is maintained under our mild fluorophore cleavage condition.

[0149] 2.4. Simultaneous HRP deactivation and fluorophore cleavage

[0150] To enable accurate protein expression analysis by this reiterative imaging approach, it also requires the HRP on antibodies to be deactivated after the staining images have been captured in each analysis cycle. In this way, the HRP applied in the previous cycles will not produce false positive signals in the following cycles. To evaluate whether PT A and TCEP can cleavage the fluorophore and deactivate HRP simultaneously, the inventors stained HMGB1, HDAC2, TAP43, PABPN1, hnRNP Al, Nucleolin, H4K16ac, hnRNP K, ZLF3 and Nucleophosmin with HRP labeled antibodies and the high-performance tyramide-N3-Cy5 in HeLa cells (Figure 4). All the antibodies used in this study are well validated and documented in the literature [20-29], With the PTA and TCEP treatment, over 95% of the staining signals were erased, leading to the on / off ratio of about 20: 1. After signal removal, the inventors stained the cells again with tyramide-N3-Cy5. No signal increases were observed for all the 10 proteins. These results confirm that PTA and TCEP can efficiently cleave the fluorophores in the high-performance CFT, and also suggest that HRP are almost completely deactivated simultaneously.

[0151] 2.5. Multiplexed protein imaging in cultured cells

[0152] To explore whether the high-performance CFT can be applied for multiplexed protein imaging, the inventors stained the 10 different proteins through reiterative immunofluorescence cycles in the same set of HeLa cells (Figure 5A). As controls, the inventors also stained each of those 10 target proteins using the conventional tyramide signal amplification (TSA) approach (Figure 5B). The protein distribution patterns generated by the two approaches, together with the ones obtained with antibodies from varied clones [30,31], closely resemble each other. Additionally, the mean protein expression levels per cell obtained using our and TSA methods are also consistent (Figure 6A). Comparison of the results measured by the two approaches generates an R2= 0.99 with a slope of 1.09 (Figure 6B). These results suggest that our method enables the accurate and multiplexed protein analysis in single cells in situ.

[0153] 2.6. Single-cell protein expression heterogeneity and correlation

[0154] As reported previously, a group of genetically identical cells can have varied gene expression patterns at the single cell level [32-38], To study such protein expression heterogeneity in individual HeLa cells, the inventors quantified the distribution of the protein abundances in single cells (Figure 7A). The expression levels of all the 10 analyzed proteins are distributed widely, which leads to the relatively large expression standard deviations in Figure 6. And the square of those expression standard deviations is significantly higher than the average expression levels for each measured protein. These results suggest that the protein expression in individualHeLa cells is highly heterogeneous, which may be attributed to the synthesis of those proteins in bursts

[0039] ,

[0155] To explore which proteins are coregulated in a regulatory pathway, one can perform protein expression covariation analysis. Such studies carried out in populations of cells usually require external stimuli to induce different protein expression levels in varied cell groups. With the gene expression heterogeneity naturally generated in individual cells, single-cell protein expression covariation analysis can advance our understanding of regulatory pathways and predict the potential function of unannotated proteins

[0040] , To perform such studies, the inventors calculated the pairwise expression correlation coefficient of the 10 analyzed proteins. Some protein pairs exhibit high expression correlation with the correlation efficient of ~0.8, including HDAC2 and PABPN together with PABPN and hnRNP Al. To elucidate the regulatory network among the 10 analyzed proteins, a hierarchical clustering method

[0041] was used and identified a group of 8 proteins with substantial expression correlation (Figure 7B). As reported in the literature [42- 49], those 8 proteins are indeed involved in the transcription processing and regulation pathways.

[0156] 2. 7. Multiplexed in situ protein profiling in FFPE tissues

[0157] To demonstrate the feasibility of applying the high performance CFT for multiplexed protein analysis in FFPE tissues, the inventors stained protein ILF3, Nucleophosmin, and hnRNP K through reiterative immunofluorescence cycles on a human FFPE tonsil tissue (Figure 8A). The inventors also stained these three proteins by the conventional TSA method (Figure 8B). The staining patterns and signal intensities obtained by the two approaches are consistent with each other (Figure 8D). These results indicate that multiplexed in situ protein profiling can be achieved in FFPE tissues using the high-performance CFT.

[0158] The existing reiterative protein staining approaches [7-12] require the proteins to be profiled in the order of increasing abundances, so that the leftover signals produced in the previous cycles may not interfere with the protein quantification in the following cycles. However, sometimes the amount of the precious clinical and biological samples is limited, and thus it can be impossible to have the knowledge of the relative protein expression levels in advance. Additionally, the order of the protein abundances in the varied cell types and states in the same specimen can be different. As a result, it might not be feasible to have an ideal protein analysis sequence that works for all the distinct cell types in the same specimen. Due to its high signal removal efficiency, our CFT approach may partially address those issues by eliminating the requirement of knowing the relative protein abundances in advance. To assess whether proteinscan be profiled in the order of decreasing expression levels, the inventors stained protein hnRNP K, Nucleophosmin and ILF3 sequentially on a human FFPE tonsil tissue (Figure 8C). The generated staining patterns and signal intensities of all the three proteins closely resemble the ones obtained by the conventional TSA approach (Figure 8D). These results suggest that the high signal removal efficiency of our approach enables it to partially eliminate the requirement of the prior knowledge of protein abundances and potentially allow accurate protein quantification regardless of the protein profiling order.

[0159] 3. Discussion

[0160] In summary, the inventors have design and synthesized the high performance CFT, and demonstrated it can be applied for multiplexed in situ protein profiling in culture cells and FFPE tissues. Compared the existing multiplexed protein imaging technologies, our approach has the following advantages. First, with the signal amplification by HRP, our approach has dramatically improved detection sensitivity. As a result, it enables the precise quantification of low-expression proteins in highly autofluorescent specimen, and also significantly enhance the sample throughput by reducing the imaging time. Second, as the commercially available and well validated antibodies are directly used in our approach, the time-consuming and expensive antibody-tag conjugation process is avoided. Third, by eliminating the carbamate group in the chemical structure of the high- performance CFT, the potential side reactions during CFT storage and protein staining are minimized. Finally, with the enhanced signal removal efficiency under a mild condition, our approach could allow multiple proteins to be precisely quantified regardless of the protein analysis order.

[0161] The multiplexing capacity of our approach depends on the number of reiterative analysis cycles and the number of proteins profiled in each cycle. The inventors have shown that the protein antigeneity is preserved after the PTA overnight incubation, and the inventors also documented previously that the integrity of the epitopes is maintained following the TCEP treatment for 24 hours [8], As each signal removal reaction only requires 30 minutes of the PTA and TCEP incubation, the inventors envision that at least 20 to 30 reiterative cycles can be performed on the same sample. In each analysis cycle, after staining the different protein targets using CFT with varied fluorophores, the HRP can be deactivated

[0050] or the antibodies can be stripped

[0051] using the established methods. In this way, four or five different proteins can be quantified in each cycle. As a result, the inventors anticipate that our approach has the potential to enable -100 proteins to be profiled in the same specimen.

[0162] The high-performance CFT developed here can also be applied for in situ analysis of nucleic acids

[0052] and metabolics

[0053] , By integrating these applications with protein analysis, the combined DNA, RNA, protein and metabolic analysis can be achieved in single cells in their natural spatial contexts. This highly multiplexed in situ molecular profiling platform will bring new insights into systems biology, biomedical research and precision medicine.

[0163] References

[0164] 1. Steininger, R.J.; Rajaram, S.; Girard, L.; Minna, J.D.; Wu, L.F.; Altschuler, S.J. On comparing heterogeneity across biomarkers. Cytom. Part A 2015, 57, 558-567, doi: 10.1002 / cyto.a.22599.

[0165] 2. Junker, J.P.; Van Oudenaarden, A. Every cell is special: Genome- wide studies add a new dimension to single-cell biology. Cell 2014, 157, 8-11, doi : 10.1016 / j . cell.2014.02.010.

[0166] 3 LaBaer, J.; Ramachandran, N. Protein microarrays as tools for functional proteomics. Curr. Opin. Chem. Biol. 2005, 9, 14-19. doi: 10.1016 / j.cbpa.2004.12.006.

[0167] 4. Altelaar, a F.M.; Munoz, J.; Heck, A. J.R. Next-generation proteomics: towards an integrative view of proteome dynamics. Nat. Rev. Genet. 2012, 14, 35-48, doi:10.1038 / nrg3356.

[0168] 5. Guo, J.; Wang, S.; Dai, N.; Teo, Y.N.; Kool, E.T. Multispectral labeling of antibodies with polyfluorophores on a DNA backbone and application in cellular imaging. Proc. Natl. Acad. Sci. 2011, 108, 3493-3498, doi: 10.1073 / pnas.1017349108.

[0169] 6. Angelo, M.; Bendall, S.C.; Finck, R.; Hale, M B.; Hitzman, C.; Borowsky, A.D.;Levenson, R.M.; Lowe, J.B.; Liu, S.D.; Zhao, S.; et al. Multiplexed ion beam imaging of human breast tumors. Nat. Med. 2014, 20, 436-442, doi: 10.1038 / nm.3488.

[0170] 7. Robertson, D.; Savage, K.; Reis-Filho, J.S.; Isacke, C.M. Multiple immunofluorescence labeling of formalin-fixed paraffin-embedded tissue. BMC Mol. Biol. 2008, 9, 1-10, doi: 10.1007 / 978-l-61779-055-3_4.

[0171] 8. Mondal, M.; Liao, R.; Xiao, L.; Eno, T.; Guo, J. Highly Multiplexed Single-Cell InSitu Protein Analysis with Cleavable Fluorescent Antibodies. Angew. Chemie Int. Ed. 2017, 56, 2636-2639, doi : 10.1002 / anie.201611641.

[0172] 9. Schweller, R.M.; Zimak, J.; Duose, D.Y.; Qutub, A. a; Hittelman, W.N.; Diehl,M.R. Multiplexed in situ immunofluorescence using dynamic DNA complexes. Angew. Chem. Int. Ed. Engl. 2012, 51, 9292-9296, doi: 10.1002 / anie.201204304.

[0173] 10. Duose, D.Y.; Schweller, R.M.; Zimak, J.; Rogers, A R.; Hittelman, W.N.; Diehl,M.R. Configuring robust DNA strand displacement reactions for in situ molecular analyses. Nucleic Acids Res. 2012, 40, 3289-3298, doi: 10.1093 / nar / gkrl209.

[0174] 11. Zrazhevskiy, P.; Gao, X. Quantum dot imaging platform for single-cell molecular profiling. Nat. Cornmun. 2013, 4, 1619, doi: 10.1038 / ncomms2635.

[0175] 12. Lin, J.R.; Fallahi-Sichani, M.; Sorger, P.K. Highly multiplexed imaging of single cells using a high-throughput cyclic immunofluorescence method. Nat. Commun. 2015, 6, 1-7, doi: 10.1038 / ncomms9390.

[0176] 13. Goltsev, Y.; Samusik, N.; Kennedy -Darling, J.; Bhate, S.; Hale, M.; Vazquez, G.;Black, S.; Nolan, G.P. Deep Profiling of Mouse Splenic Architecture with CODEX Multiplexed Imaging. Ct? / / 2018, 174, 968-981. el5, doi: 10.1016 / j .cell.2018.07.010.

[0177] 14. Giesen, C .; Wang, H. a O.; Schapiro, D.; Zivanovic, N.; Jacobs, A.; Hattendorf, B.;Schiiffler, P.J.; Grolimund, D.; Buhmann, J.M.; Brandt, S.; et al. Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry. Nat. Methods 2014, 11, 417-422, doi : 10.1038 / nmeth.2869.

[0178] 15. Liao, R.; Pham, T.; Mastroeni, D.; Coleman, P.D.; Labaer, J.; Guo, J. HighlySensitive and Multiplexed In-Situ Protein Profiling with Cleavable Fluorescent Streptavidin. Cells 2020, 9, 852, doi: 10.3390 / cells9040852.

[0179] 16. Saka, S.K.; Wang, Y.; Kishi, J.Y.; Zhu, A.; Zeng, Y.; Xie, W .; Kirli, K.; Yapp, C.;Cicconet, M.; Beliveau, B.J.; et al. Immuno-SABER enables highly multiplexed and amplified protein imaging in tissues. Nat. Biotechnol. 2019, 37, 1080-1090, doi: 10.1038 / s41587-019-0207- y-

[0180] 17. Liao, R.; Mondal, M.; Nazaroff, C.D.; Mastroeni, D.; Coleman, P.D.; Labaer, J.;Guo, J. Highly Sensitive and Multiplexed Protein Imaging With Cleavable Fluorescent Tyramide Reveals Human Neuronal Heterogeneity. Front. Cell Dev. Biol. 2021, 8, 1—15, doi : 10.3389 / fcell .2020.614624.

[0181] 18. Mondal, M.; Liao, R.; Nazaroff, C.D.; Samuel, A.D.; Guo, J. Highly multiplexed single-cell in situ RNA and DNA analysis with bioorthogonal cleavable fluorescent oligonucleotides. Chem. Sci. 2018, 9, 2909-2917, doi: 10.1039 / C7SC05089E.

[0182] 19. Jun, Y.W.; Kim, H R.; Reo, Y.J.; Dai, M.; Ahn, K.H. Addressing the autofluorescence issue in deep tissue imaging by two-photon microscopy: The significance of far- red emitting dyes. Chem. Sci. 2017, 8, 7696-7704, doi:10.1039 / c7sc03362a.

[0183] 20. Lin, Y.H.; Yao, M.C.; Wu, H.Y.; Dong, I; Ni, H.Y.; Kou, XL; Chang, L.; Luo,C.X.; Zhu, D.Y. HDAC2 (Histone deacetylase 2): A critical factor in environmental enrichment- mediated stroke recovery. J. Neurochem. 2020, 155, 679-696. doi: 10.1111 / jnc.15043.

[0184] 21. Zhao, L.; Ke, H.; Xu, H; Wang, G.D.; Zhang, H.; Zou, L.; Xiang, S.; Li, M.; Peng,L.; Zhou, M.; et al. TDP-43 facilitates milk lipid secretion by post-transcriptional regulation of Btnlal and Xdh. Nat. Commun. 2020, 11, 341. doi: 10.1038 / s41467-019-14183-1.

[0185] 22. Harish, P.; Forrest, L.; Herath, S.; Dickson, G.; Malerba, A.; Popplewell, L.Inhibition of Myostatin Reduces Collagen Deposition in a Mouse Model of Oculopharyngeal Muscular Dystrophy (OPMD) With Established Disease. Front. Physiol. 2020, 11, 184. doi:10.3389 / fphys.2020.00184.

[0186] 23. Jia, Q.; Nie, H.; Yu, P.; Xie, B.; Wang, C.; Yang, F.; Wei, G.; Ni, T. HNRNPA1- mediated 3’ UTR length changes of HN1 contributes to cancer- and senescence-associated phenotypes. Aging (Albany. NY). 2019, 11, 4407-4437, doi : 10.18632 / aging.102060.

[0187] 24. Dubois, M.L.; Meller, A.; Samandi, S.; Brunelle, M.; Frion, J.; Brunet, M.A.;Toupin, A.; Beaudoin, M.C.; Jacques, J.F.; Levesque, D.; et al. UBB pseudogene 4 encodes functional ubiquitin variants. Nat. Commun. 2020, 11, 1306. doi: 10.1038 / s41467-020-15090-6.

[0188] 25. Li, L.; Ghorbani, M.; Weisz-Hubshman, M.; Rousseau, J.; Thiffault, I.; Schnur,R.E.; Breen, C.; Oegema, R.; Weiss, M.M.M.; Waisfisz, Q.; et al. Lysine acetyltransferase 8 is involved in cerebral development and syndromic intellectual disability. J. Clin. Invest. 2020, 130, 1431-1445, doi: 10.1172 / JCI131145.

[0189] 26. Pellegrini, L.; Hauser, D.N.; Li, Y.; Mamais, A.; Beilina, A.; Kumaran, R.; Wetzel,A.; Nixon-Abell, J.; Heaton, G.; Rudenko, I.; et al. Proteomic analysis reveals co-ordinated alterations in protein synthesis and degradation pathways in LRRK2 knockout mice. Hum. Mol. Genet. 2018, 27, 3257-3271, doi: 10.1093 / hmg / ddy232.

[0190] 27. Watson, S.F.; Bellora, N.; Macias, S. ILF3 contributes to the establishment of the antiviral type i interferon program. Nucleic Acids Res. 2020, 48, 116-129, doi: 10.I093 / nar / gkzI060.

[0191] 28. Chen, Q.; Xi, X.; Zeng, Y.; He, Z.; Zhao, J.; Li, Y. Acteoside inhibits autophagic apoptosis of retinal ganglion cells to rescue glaucoma-induced optic atrophy. J. Cell. Biochem. 2019, 120, 13133-13140, doi: 10.1002 / jcb.28586.

[0192] 29. Maugeri, N.; Campana, L.; Gavina, M.; Covino, C.; De Metric, M.; Panciroli, C.;Maiuri, L.; Maseri, A.; D’Angelo, A.; Bianchi, M.E.; et al. Activated platelets present highmobility group box 1 to neutrophils, inducing autophagy and promoting the extrusion of neutrophil extracellular traps. J. Thronib. Haemost. 2014, 12, 2074-2088, doi: 10.1111 / jth.12710.

[0193] 30. Uhlen, M.; Fagerberg, L.; Hallstrom, B.M.; Lindskog, C.; Oksvold, P.; Mardinoglu,A.; Sivertsson, A.; Kampf, C.; Sjostedt, E.; Asplund, A.; et al. Tissue-based map of the human proteome. Science 2015, 347, 1260419, doi: 10.1126 / science.1260419.

[0194] 31. Thul, P.J.; Akesson, L.; Wiking, M.; Mahdessian, D.; Geladaki, A.; Ait Blal, H.;Alm, T.; Asplund, A.; Bjork, L.; Breckels, L.M.; et al. A subcellular map of the human proteome. Science. 2017, 356, doi: 10.1126 / science. aal3321.

[0195] 32. Becskei, A.; Kaufmann, B.B.; van Oudenaarden, A. Contributions of low molecule number and chromosomal positioning to stochastic gene expression. Nat. Genet. 2005, 37, 937- 944, doi: 10.1038 / ngl616.

[0196] 33. Blake, W.J.; KAEm, M.; Cantor, C.R.; Collins, J. J. Noise in eukaryotic gene expression. Nature 2003, 422, 633-637, doi: 10.1038 / nature01546.

[0197] 34. Elowitz, M.B.; Levine, A.J.; Siggia, E.D.; Swain, P.S. Stochastic gene expression in a single cell. Science 2002, 297, 1183-1186, doi: 10.1126 / science.1070919.

[0198] 35. Golding, I .; Paulsson, J.; Zawilski, S.M.; Cox, E.C. Real-time kinetics of gene activity in individual bacteria. Cell 2005, 123, 1025-1036, doi: 10.1016 / j. cell.2005.09.031.

[0199] 36. Ozbudak, E.M.; Thattai, M.; Kurtser, I.; Grossman, A.D.; van Oudenaarden, A.Regulation of noise in the expression of a single gene. Nat. Genet. 2002, 31, 69-73, doi: 10.1038 / ng869.

[0200] 37 Raser, J.M.; O’Shea, E.K. Control of stochasticity in eukaryotic gene expression.Science 2004, 304, 1811-1814, doi: 10.1126 / science.1098641.

[0201] 38. Rosenfeld, N.; Young, J.W.; Alon, U; Swain, P.S.; Elowitz, M.B. Gene Regulation at the Single-Cell Level. Science 2005, 307, 1962-1965.

[0202] 39. Raj, A.; Peskin, C.S.; Tranchina, D.; Vargas, D.Y.; Tyagi, S. Stochastic mRNA synthesis in mammalian cells. PLoSBiol. 2006, 4, 1707-1719, doi: 10.1371 / joumal.pbio.0040309.

[0203] 40. Munsky, B.; Neuert, G.; van Oudenaarden, a. Using Gene Expression Noise toUnderstand Gene Regulation. Science. 2012, 336, 183-187, doi: 10.1126 / science.1216379.

[0204] 41. Eisen, Michael B., Spellman, Paul T., Brown, Patrick O., Botstein, D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA 1998, 95, 14863-14868.

[0205] 42. Jahan, S.; Sun, J -M ; He, S.; Davie, J.R. Transcription-dependent association ofHDAC2 with active chromatin. J. Cell. Physiol. 2018, 233, 1650-1657, doi: 10.1002 / jcp.26078.

[0206] 43. Lalmansingh, A.S.; Urekar, C.J.; Reddi, P.P. TDP-43 is a transcriptional repressor: the testis-specific mouse acrvl gene is a TDP-43 target in vivo. J. Biol. Chem. 2011, 286, 10970- 10982, doi:10.1074 / jbc. Ml 10.166587.

[0207] 44. Jean-Philippe, J.; Paz, S.; Caputi, M. hnRNP Al : the Swiss army knife of gene expression. Ini. J. Mol. Sci. 2013, 14, 18999-19024, doi:10.3390 / ijmsl40918999.

[0208] 45. Abdelmohsen, K.; Gorospe, M. RNA-binding protein nucleolin in disease. RNABiol. 2012, 9, 799-808, doi:10.4161 / ma, 19718.

[0209] 46. Box, J.K.; Paquet, N.; Adams, M.N.; Boucher, D.; Bolderson, E.; O’Byrne, K.J.;Richard, D.J. Nucleophosmin: from structure and function to disease development. BMC Mol. Biol. 2016, 17, 19, doi: 10.1186 / sl2867-016-0073-9.

[0210] 47. Banerjee, A.; Apponi, L.H.; Pavlath, G.K.; Corbett, A.H. PABPN1 : molecular function and muscle disease. FEBSJ. 2013, 280, 4230-4250, doi: 10.1111 / febs. 12294.

[0211] 48. Castella, S.; Bernard, R.; Corno, M.; Fradin, A.; Larcher, J.-C. Ilf3 and NF90 functions in RNA biology. Wiley Interdiscip. Rev. RNA 2015, 6, 243-256, doi: 10.1002 / wrna.1270.

[0212] 49. Lu, J.; Gao, F.-H. Role and molecular mechanism of heterogeneous nuclear ribonucleoprotein K in tumor development and progression. Biomed. reports 2016, 4, 657-663, doi: 10.3892 / br.2016.642.

[0213] 50. Liu, G.; Amin, S.; Okuhama, N.N.; Liao, G.; Mingle, L A. A quantitative evaluation of peroxidase inhibitors for tyramide signal amplification mediated cytochemistry and histochemistry. Histochem. Cell Biol. 2006, 126, 283-291, doi: 10.1007 / s00418-006-0161-x.

[0214] 51. Stack, E.C.; Wang, C.; Roman, K.A.; Hoyt, C.C. Multiplexed immunohistochemistry, imaging, and quantitation: A review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis. Methods 2014, 70, 46-58, doi: 10.1016 / j.ymeth.2014.08.016.

[0215] 52. van de Corput, M.P.; Dirks, R.W.; van Gijlswijk, R.P.; van de Rijke, F.M.; Raap,A.K. Fluorescence in situ hybridization using horseradish peroxidase-labeled oligodeoxynucleotides and tyramide signal amplification for sensitive DNA and mRNA detection. Histochem. Cell Biol. 1998, 110, 431-437.

[0216] 53. Xue, M.; Wei, W ; Su, Y.; Kim, J.; Shin, Y.S.; Mai, W.X.; Nathanson, D a.; Heath,J.R. Chemical methods for the simultaneous quantitation of metabolites and proteins from single cells. J. Am. Chem. Soc. 2015, 137, 4066-4069, doi: 10.1021 / jacs.5b00944.Example 2: Ultrasensitive and multiplexed protein imaging with cleavable fluorescent tyramide and antibody stripping

[0217] In the current technology, the inventors disclose a technique for ultrasensitive and multiplexed in situ protein identification and quantification procedure using off the shelf antibodies and cleavable fluorescent tyramide (CFT). This technology achieves the detection of large number of varied proteins including low expressing proteins and quantifying them in their native state through continuous cycles of target staining, fluorescence imaging, signal removal and antibody staining. This scores over other protein detection / quantitation tools where isolation of protein is required leading to loss of information about its localization.

[0218] Illustrative features and advantages of embodiments of the present technology include, without limitation:• Multiplexed and ultrasensitive technique for quantifying and detecting single cell protein in their native state.• Ability to use off the shelf commercial antibodies.• Involves repeated cycles of protein target stain using HRP conjugated antibodies and CFT.• After image capture, the staining is erased using fluorophore cleavage and simultaneous HRP inactivation.• After all the targets are stained in the first cycle, the proteins are stripped to be used for second round of staining.• Potentially up to 10 protein targets can be quantified in one analysis cycle. o Four or Five CFT consisting of distinct fluorophores applied in each cycle. o Together with repeated protein staining and fluorophore cleavage.• This multiplex protein detection technology involving continuous cycles of staining, imaging, fluorophore cleavage and antibody stripping can be used for 20 times while retaining integrity of the protein.• This technique has high sensitivity due to enzymatic amplification and eliminates the use of conjugating primary antibody and can be used for identifying cell types and subtypes for better patient stratification and disease diagnosis.• In some embodiments, the analysis cycle can be divided into six steps.o First, the different proteins of interest are recognized by primary antibodies from distinct species or of varied immunoglobulin classes. o Second, one of protein targets is stained with primary or secondary antibodies conjugated with HRP, which catalyzes the coupling reactions between the tyramide moiety in CFT and the tyrosine residues on the proteins proximal to the target. o Third, images of the specimen are captured under a fluorescence microscope to generate quantitative single-cell protein expression profdes. To facilitate the alignment of different protein staining images, the nucleus stained with DAPI are imaged together with the protein target. o Fourth, the fluorophores are cleaved by a chemical reaction, and HRP is deactivated simultaneously. o Fifth, steps two to four are repeated until every protein target in the first analysis cycle is quantified. o Sixth, all the antibodies are stripped to initiate the next cycle.

[0219] Multiplexed single-cell protein analysis in their native cellular contexts holds great promise to reveal the composition, interaction and function of the distinct cell types in complex biological systems. However, the existing multiplexed protein imaging technologies are limited by their detection sensitivity or technically demanding. To address these issues, here the inventors develop an ultra-sensitive and multiplexed in situ protein profiling approach by reiterative staining with off-the-shelf antibodies and cleavable fluorescent tyramide (CFT). In each cycle of this approach, the protein targets are recognized by antibodies labeled with horseradish peroxidase, which catalyze the covalent deposition of CFT on or close to the protein targets. After imaging, the fluorophores are chemically cleaved and the antibodies are stripped. Through continuous cycles of staining, imaging, fluorophore cleavage and antibody stripping, a large number of proteins can be quantified in individual cells in situ. Applying this method, the inventors analyzed 20 different proteins in each of -67,000 cells in a human formalin fixed paraffin-embedded (FFPE) tonsil tissue. Based on their unique protein expression profiles and microenvironment, these individual cells are partitioned into different cell clusters. The inventors also explored the cell-cell interactions in the tissue by examining which specific cell clusters are selectively associating or avoiding each other.

[0220] Understanding the composition, interaction and regulations of complex biological systems require tools that quantify the abundances of multiple proteins in single cells in their nativecellular context [1-3], Mass spectrometry [4] and protein microarray [5] are powerful technologies for comprehensive protein analysis. Nonetheless, these approaches require proteins to be purified and isolated from other cellular components as sample preparation prior to its analysis. Consequently, the protein location information in the biological system is lost. Immunofluorescence is a well-established method for profiling proteins in situ. However, as a result of the spectral overlap of the common fluorophores [6], only a handful of different proteins can be visualized by immunofluorescence in one specimen.

[0221] To enable multiplexed protein imaging, a number of methods have been developed recently. In these techniques [7-16], fluorophores or metal isotopes conjugated primary antibodies are applied to stain the protein targets. Without signal amplification, the low detection sensitivity of these methods limits their applications to study low-expression proteins or to examine specimens with high autofluorescence, such as formalin-fixed paraffin-embedded (FFPE) tissues

[0017] , To tackle these issues, several laboratories including ours have developed several sensitive and multiplexed protein imaging technologies by signal amplifications with biotin-streptavidin interaction

[0018] , oligonucleotide hybridization

[0019] , and horseradish peroxidase (HRP) [20,21], However, these methods require a chemical, oligonucleotide or HRP labeled primary antibodies to recognize the protein targets. Such conjugated primary antibodies are usually not commercially available, and to prepare those primary antibodies labeled with the desired tag can be technically demanding, time consuming and costly. Additionally, these bulky tags on the primary antibodies can interfere with their binding specificity and affinity, leading to false negative and positive staining signals.

[0222] Here, the inventors report a highly sensitive and multiplexed in situ protein profiling approach using cleavable fluorescent tyramide (CFT) and off-the-shelf antibodies. In this approach, protein targets are stained with HRP conjugated antibodies and CFT. Following image capture, the staining signals are erased by fluorophore cleavage. And simultaneously, HRP are deactivated. After all the targets are stained in the first cycle, the antibodies are stripped to initiate the second cycle. Through reiterative cycles of target staining, fluorescence imaging, signal removal and antibody stripping, a large of varied proteins can be quantified in their native spatial contexts at the optical resolution. To demonstrate the feasibility of this approach, the inventors show that the microwaving-mediated stripping can efficiently remove the antibodies, and maintain the epitope integrity for at least 20 analysis cycles. Applying this approach, the inventors quantified 20 different proteins in -67,000 individual cells in a human FFPE tonsil tissue. Basedon their unique protein expression profiles and their neighbor cells, these single cells are partitioned into varied cell clusters. By mapping the cell clusters back to their original tissue locations, the inventors observe that different subregions of the tissue are composed of cells from different clusters. The inventors also studied the cell-cell interactions in the tonsil tissue by identifying the association and avoidance among the specific cell clusters.

[0223] Multiplexed single-cell protein analysis in their native cellular contexts holds great promise to reveal the composition, interaction and function of the distinct cell types in complex biological systems. However, the existing multiplexed protein imaging technologies are limited by their detection sensitivity or technically demanding. To address these issues, here the inventors develop an ultra-sensitive and multiplexed in situ protein profding approach by reiterative staining with off-the-shelf antibodies and cleavable fluorescent tyramide (CFT). In each cycle of this approach, the protein targets are recognized by antibodies labeled with horseradish peroxidase, which catalyze the covalent deposition of CFT on or close to the protein targets. After imaging, the fluorophores are chemically cleaved and the antibodies are stripped. Through continuous cycles of staining, imaging, fluorophore cleavage and antibody stripping, a large number of proteins can be quantified in individual cells in situ.

[0224] This approach allows the classification of cell types and subtypes based on their protein expression profiles and neighbor cells. These identified cell types and subtypes will bring new insights into cell heterogeneity studies, disease diagnosis, and patient stratification.

[0225] By applying antibody stripping and CFT, our approach enables the large number of the commercially available unconjugated primary antibodies to be directly applied in the assay. Thus, our approach can be easily adopted by the research laboratories and in clinical settings. In comparison with the current multiplexed protein imaging technologies, our approach has ultrahigh detection sensitivity by the enzymatic signal amplification. As a result, low expression proteins or the targets in highly autofluorescent tissues can be accurately quantified.

[0226] In addition, by eliminating the requirement of the sophisticated chemical conjugation of the primary antibodies, the binding specificity and affinity of the anti-bodies are maintained. And by enabling the large number of the commercially available unconjugated primary antibodies to be directly applied in the assay, our approach can be easily adopted by the research laboratories and in clinical settings.

[0227] The present invention has been described in terms of one or more preferred embodiments, and it should be appreciated that many equivalents, alternatives, variations, and modifications, aside from those expressly stated, are possible and within the scope of the invention. ResultPlatform Design

[0228] As shown in Figure 9A, this multiplexed in situ protein profiling technology has six major steps in each analysis cycle. First, the different proteins of interest are recognized by primary antibodies from distinct species or of varied immunoglobulin classes. Second, one of protein targets is stained with primary or secondary antibodies conjugated with HRP, which catalyzes the coupling reactions between the tyramide moiety in CFT and the tyrosine residues on the proteins proximal to the target. Third, images of the specimen are captured under a fluorescence microscope to generate quantitative single-cell protein expression profiles. To facilitate the alignment of different protein staining images, the nucleus stained with DAPI are imaged together with the protein target. Fourth, the fluorophores are cleaved by a chemical reaction, and HRP is deactivated simultaneously. Fifth, steps two to four are repeated until every protein target in the first analysis cycle is quantified. Finally, all the antibodies are stripped to initiate the next cycle. Through reiterative cycles of protein staining, fluorescence imaging, fluorophore cleavage, HRP deactivation and antibody stripping, highly sensitive and multiplexed in situ protein profiling can be achieved in single cells of intact tissues. Efficient antibody stripping while preserving epitope integrity

[0229] One aspect to consider for the success of this method is to efficiently strip the antibodies, so that the antibodies applied in the previous cycles will not result in false positive signals in the following cycles. To assess the antibody stripping efficiency, the inventors stained 20 different proteins in human FFPE tonsil tissues with HRP conjugated antibodies and CFT (Figure 10). Subsequently, the fluorophores were cleaved using a mild chemical reaction with l,3,5-Triaza-7- phosphaadamantane (PTA) and tris(2-carboxyethyl)phosphine (TCEP). Following signal removal, almost all the staining signals are erased, confirming the high cleavage efficiency of the CFT as the inventors reported before. The inventors also documented that this chemical reaction does not damage the epitope integrity, which allows other proteins to be accurately profiled in the later cycles. Following fluorophore cleavage, the antibodies were removed by microwave-mediated stripping. Afterwards, the tissues were re-incubated with HRP conjugated antibodies and CFT.However, no signal increase was observed. These results indicate that the antibodies applied for protein staining can be efficiently removed by microwave-mediated stripping.

[0230] Another aspect to consider for this approach to succeed is that the epitope integrity must be maintained under this antibody stripping condition. In this way, the stripping process applied in the prior cycles will not interfere with the precise protein profiling in the later cycles. To evaluate the effects of antibody stripping on epitope integrity, the inventors stained proteins hnRNP K, Nucleophosmin and Bcl2 in the same human FFPE tonsil tissue, after 10, 15 and 20 cycles of antibody stripping, respectively (Figure 11 A). As positive controls, the inventors also stained the same three proteins in three FFPE tonsil tissues using the conventional tyramide signal amplification approach. The staining patterns and signal intensities (Figure 1 IB) obtained by the two methods are consistent with each other. These results suggest that the epitope integrity is preserved after at least 20 cycles of antibody stripping.Multiplexed in situ protein profiling in FFPE tissues

[0231] To demonstrate the feasibility of applying this approach for multiplexed in situ proteinprofiling in FFPE tissues, the inventors stained 20 different proteins using off-the-shelf HRP conjugated antibodies and CFT in the same FFPE human tonsil tissue (Figure 12). All the 20 proteins were successfully stained and unambiguously detected with the subcellular resolution. The obtained protein staining patterns are consistent with the ones generated by staining each protein in different tissues (Figure 10). Due to its high detection sensitivity resulting from the HRP signal amplification, our approach allows the imaging time to be dramatically reduced while maintaining the analysis accuracy. By automatic whole slide scanning with the fluorescence microscope, to image this tissue (~2 mm x 4 mm) only takes less than 10 min. In comparison, the current mass spectrometry imaging methods require ~64 h to image the tissue with the similar sizes. These results indicate that our approach enables highly sensitive and multiplexed in situ protein profiling in FFPE tissues with short assay time and high sample throughput.Different cell types and their spatial distribution in the human tonsil tissue

[0232] The generated single-cell in situ protein expression profiles also allow us to study cell heterogeneity and the spatial distribution of the various cell types in human tonsil tissues. To achieve that, the inventors calculated the expression levels of the 20 examined proteins in each of ~67, 000 cells identified in the tissue. Based on their unique protein expression patterns (Figure 13A and Figure 15), those individual cells were partitioned into 10 different cell clusters (Figure13B) using the software viSNE. The inventors then mapped these 10 cell culters back to their natural tissue locations (Figure 13C and Figure 16), and observed that the varied subregions of tonsil tissue are composed of cells from distinct clusters. For instance, cluster 7 is the major cell type in epithelium. The germinal centers mainly consist of clusters 8 and 10, while the lymph nodules are dominated by clusters 5, 6 and 9. And clusters 1 and 4 only appear in connetive tissues. These results indicate that our approach enables the study of cell type classification and their spatial distribution in FFPE tissues.Cell-cell interactions in the human tonsil tissue

[0233] With the proteins profiled at their native spatial contexts, our approach also allows the investigation of cell-cell contacts between different cell clusters (Figure 14A). To achieve that, the inventors defined the cell neighborhood as all the cells within the 20 pm distance of a central cell. For the ~67, 000 individual central cells in the human tonsil tissue, the inventors counted the cell number from varied clusters in each of the cell neighborhoods. The inventors then calculated the correlation coefficient of those cell numbers between each pair of the different cell clusters. When displayed in the heatmap, the metric revealed that some cell clusters are selectively associated with or avoiding each other. For example, a significant association was observed between cell clusters 2 and 3, 5 and 9, together with 8 and 10; while an avoidance of contact was revealed between cell clusters 1 and 3, 1 and 8, along with 1 and 10. Interestingly, the inventors observed a consistently strong association between the cells from same cell cluster (Figure 14A, diagonal), indicating that homotypic cell adhesion may play an important role to form the architecture of the human tonsil tissue.

[0234] Based on the cell number from the distinct clusters in their neighborhoods (Figure 14B and Figure 17), the single cells in the same cluster can be partitioned into subclusters (Figure 14C and Figure 17). By mapping these newly identified cell subclusters back to their native tissue locations, the inventors observed the different subclusters from the same cell cluster are located at the varied subregions of the tonsil tissue (Figure 17). For example, subcluster 10a mainly appears in the germinal centers; the majority of subcluster 10b is observed at the lymph nodules; while almost all the subcluster 10c is located in connective tissues (Figure 14D). These results suggest that our approach allows the investigation of cell-cell contact and the cell type classification based on their microenvironment.Discussion

[0235] Tn this study, the inventors have demonstrated that ultrasensitive and multiplexed in situ protein profiling can be successfully achieved in single cells of FFPE tissues using CFT and antibody stripping. In comparison with the current multiplexed protein imaging technologies, our approach has ultrahigh detection sensitivity by the enzymatic signal amplification. As a result, low expression proteins or the targets in highly autofluorescent tissues can be accurately quantified. In addition, by eliminating the requirement of the sophisticated chemical conjugation of the primary antibodies, the binding specificity and affinity of the antibodies are maintained. And by enabling the large number of the commercially available unconjugated primary antibodies to be directly applied in the assay, our approach can be easily adopted by the research laboratories and in clinical settings.

[0236] Applying this method, the inventors have shown that the individual cells in the human tonsil tissue can be classified into different cell clusters based on their unique multiplexed protein expression profiles. And the varied subregions of the tonsil tissue consist of cells from different clusters. The inventors also explored which cell clusters are associating or avoiding each other. Depending on the distinct cell clusters of their neighbor cells, the single cells in each cluster are further partitioned into varied subclusters. These results suggest that our approach allows the classification of cell types and subtypes based on their protein expression profiles and neighbor cells. These identified cell types and subtypes will bring new insights into cell heterogeneity studies, disease diagnosis, and patient stratification.

[0237] The multiplexing capacity of this protein imaging technology depends on the cycling number and the number of proteins interrogated in each analysis cycle. Here the inventors demonstrated that the integrity of the protein epitopes is maintained after at least 20 times of protein stripping. Recently, the inventors also reported that the PTA and TCEP treatment does not damage the epitopes. These results suggest more than 20 analysis cycles can be performed on one tissue sample. In each cycle, the protein targets can be stained with primary antibodies from different species or of varied immunoglobulin classes, hapten or HRP conjugated primary antibodies. With four or five CFT consisting of distinct fluorophores applied in each cycle, together with repeated protein staining and fluorophore cleavage, potentially up to 10 protein targets can be quantified in one analysis cycle. As a result, the inventors envision that this multiplexed protein imaging method has the potential to profile hundreds of varied protein targets in the same specimen.

[0238] This in situ protein analysis method can also be combined with the nucleic acids and metabolic imaging technologies, to enable the integrated DNA, RNA, protein and metabolic profiling in single cells of intact tissues. Moreover, a program-controlled microfluidic system together with a standard fluorescence microscope can easily make an automatic tissue imaging platform. This highly multiplexed molecular imaging system will have wide applications in systems biology and biomedical studies.Materials and MethodsGeneral information

[0239] Chemicals and solvents were purchased from Sigma-Aldrich or TCI America, and were used directly without further purification. Bioreagents were purchased from Abeam, Invitrogen, or Novus Biology, unless otherwise noted.Deparaffnization and antigen retrieval of FFPE tonsil tissue.

[0240] After heated at 60°C for 1 h, Tonsil FFPE tissue slides were deparaffinized in xylene three times, each for 10 minutes. The slide was then immersed successively in 50 / 50 xylene / ethanol for 2 minutes, 100% ethanol for 2 minutes, 95% ethanol for 2 minutes, and 70% ethanol for 2 minutes. The slides were rinsed with deionized water. Thereafter, heat induced antigen retrieval (HIAR) was performed using a microwave. The slide was immersed in antigen retrieval citrate buffer (Abeam ab64236) and heated in the microwave for 2 minutes and 45 seconds at high power (level 10) and 14 minutes at low power (level 2). After cooling to room temperature for 20 minutes, the slide was incubated with 3% H2O2 in PBT (0.1% Triton-X 100 in IX phosphate buffer saline (PBS)) to deactivate endogenous horse radish peroxidase (HRP) for 10 minutes. Subsequently, the slide was washed with PBT for 5 minutes twice before proceeding to Immunofluorescence with CFT.Protein staining in FFPE tonsil tissue

[0241] The slides were incubated with antibody blocking buffer (0.1% (vol / vol) Triton X-100, 1% (wt / vol) bovine serum albumin and 10% (vol / vol) normal goat serum) at room temperature for 30 min. Subsequently, the slides were incubated with 5 pg / mL of primary antibody (Table 1) in antibody blocking buffer for 1 h, followed by 3 times of 5 min washes with PBT. Then, the slides were incubated with 10 pg / mL of goat anti-rabbit, HRP or goat anti-mouse, HRP (Table 1) in antibody blocking buffer for 1 h, and then washed 3 times with PBT, each for 5 min. Afterwards, the slide were stained with tyramide-N3-Cy5 at the concentration of 10 nmol / mL in amplification buffer (0.003 % H2O2, 0.1% Tween-20, in 100 mM borate, pH = 8.5) for 10 minutes at roomtemperature, and then washed twice with PBT, each for 5 min. The tissues were stained with DAPI and mounted with Prolong Diamond Antifade Mountant before proceeding to imaging.Table 1: The antibodies used in this studyFluorophore cleavage and HRP deactivation

[0242] The stained tissues were incubated with 100 mM l,3,5-Triaza-7-phosphaadamantane (PTA) and 100 mM tris(2-carboxyethyl)phosphine (TCEP) for 30 minutes sequentially at 40°C. Subsequently, the slides were washed 3 times with PBT and IX PBS, each for 5 min.Antibody Stripping

[0243] The slides were immersed in antigen retrieval citrate buffer (Abeam ab64236) and heated in the microwave for 2 min and 45 seconds at high power (700 Watt, level 10) and 14 min at low power (140 Watt, level 2). Then, the tissues were cooled down to room temperature for 20 min.Imaging and Data Analysis

[0244] FFPE Tonsil tissues were imaged under a Nikon Ti-E epifluorescence microscope equipped with a 20x objective. Images were captured using a CoolSNAP HQ2 camera and C-FL DAPI HC HISN together with Chroma 49009 filters. Image data was processed with NIS-Elements Imaging software. The DAPI images in every cycle were used as coordination reference for aligning the images from different cycles. For the single-cell protein expression profiles, cells were segmented based on nuclear staining by DAPI using NIS-Elements Imaging software. The DAPI signals were expanded by 10 pixels for every cell to determine the regions of interest (ROIs). The signal intensity values within the ROIs of each cell were calculated using CellProfiler, and the resulting single-cell signal intensity profiles were converted into comma separated value (CSV) files. Then, these files were used for unsupervised clustering by CYT to generate ViSNE plots (https: / / www.c2b2.columbia.edu / danapeerlab / html / cyt.html). All pseudo-color images were generated with Imaged. Cell neighborhoods were calculated by detecting and classifying the surrounding cells within 20 pm or less of each individual cell in the sample. The number of cells from the different clusters in each cell neighborhood were used for clustering by CYT to generate subcluster ViSNE plots.

[0245] References

[0246] 1 Bodenmiller, B. Multiplexed Epitope-Based Tissue Imaging for Discovery andHealthcare Applications. Cell Systems 2016, 2, 225-238, doi : 10.1016 / j . cels.2016.03.008.

[0247] 2. Pham, T.; Tyagi, A.; Wang, Y.S.; Guo, J. Single-cell proteomic analysis. WileyInter discip Rev Sy st Bio 'Med 2021, 13, e!503, doi: 10.1002 / wsbm,1503.

[0248] 3. Mondal, M.; Liao, R.; Guo, J. Highly Multiplexed Single-Cell Protein Analysis.Chemistry - A European Journal 2018, 24, 7083-7091, doi: 10.1002 / chem.201705014.

[0249] 4. Altelaar, a.F.M.; Munoz, J.; Heck, A.J.R. Next-generation proteomics: towards an integrative view of proteome dynamics. Nature reviews Genetics 2012, 14, 35-48, doi: 10.1038 / nrg3356.

[0250] 5. Espina, V.; Mehta, A. I.; Winters, M.E.; Calvert, V.; Wulfkuhle, J.; Petricoin, E.F.,3rd; Liotta, L.A. Protein microarrays: molecular profiling technologies for clinical specimens. Proteomics 2003, 3, 2091-2100, doi: 10.1002 / pmic.200300592.

[0251] 6. Guo, J.; Wang, S.; Dai, N.; Teo, Y.N.; Kool, E.T. Multispectral labeling of antibodies with polyfluorophores on a DNA backbone and application in cellular imaging. Proceedings of the National Academy of Sciences of the United States of America 2011, 108, 3493-3498, doi : 10.1073 / pnas.1017349108.

[0252] 7. Schubert, W.; Bonnekoh, B.; Pommer, A. J.; Philipsen, L.; Bbckelmann, R.; Malykh,Y.; Gollnick, H.; Friedenberger, M.; Bode, M.; Dress, A.W.M. Analyzing proteome topology and function by automated multidimensional fluorescence microscopy. Nature biotechnology 2006, 24, 1270-1278, doi: 10.1038 / nbtl250.

[0253] 8. Duose, D.Y.; Schweller, R.M.; Zimak, J.; Rogers, A.R.; Hittelman, W.N.; Diehl, M.R.Configuring robust DNA strand displacement reactions for in situ molecular analyses. Nucleic Acids Res 2012, 40, 3289-3298, doi: 10.1093 / nar / gkrl209.

[0254] 9. Schweller, R.M.; Zimak, J.; Duose, D.Y.; Qutub, A.A.; Hittelman, W.N.; Diehl, M.R.Multiplexed in situ immunofluorescence using dynamic DNA complexes. Angew Chem Int Ed Engl ' 2012, 51, 9292-9296, doi:10.1002 / anie.201204304.

[0255] 10. Gerdes, M.J.; Sevinsky, C.J.; Sood, A.; Adak, S.; Bello, M.O.; Bordwell, A.; Can,A.; Corwin, A.; Dinn, S.; Filkins, R.J., et al. Highly multiplexed single-cell analysis of formalin- fixed, paraffin-embedded cancer tissue. Proceedings of the National Academy of Sciences of the United States of America 2013, 110, 11982-11987, doi: 10.1073 / pnas.1300136110.

[0256] 11. Lin, J.R.; Fallahi-Sichani, M.; Sorger, P.K. Highly multiplexed imaging of single cells using a high-throughput cyclic immunofluorescence method. Nat Commun 2015, 6, 8390, doi : 10.1038 / ncomm s9390.

[0257] 12. Mondal, M.; Liao, R.; Xiao, L.; Eno, T.; Guo, J. Highly Multiplexed Single-Cell InSitu Protein Analysis with Cleavable Fluorescent Antibodies. Angewandte Chemie International Edition 2017, 56, 2636-2639, doi:10.1002 / anie.20161164L

[0258] 13. Goltsev, Y.; Samusik, N.; Kennedy - Darling, J.; Bhate, S.; Hale, M.; Vasquez, G.;Nolan, G.P. Deep Profiling of Mouse Splenic Architecture with CODEX Multiplexed Imaging, ce / / 2018, 174, 968-981.e915, doi: 10.2139 / ssrn.3155542.

[0259] 14. Gut, G.; Herrmann, M.D.; Pelkmans, L. Multiplexed protein maps link subcellular organization to cellular states. Science 2018, 361, eaar7042-eaar7042, doi: 10.1126 / science.aar7042.

[0260] 15. Angelo, M.; Bendall, S.C.; Finck, R.; Hale, M.B.; Hitzman, C.; Borowsky, A.D.;Levenson, R.M.; Lowe, J.B.; Liu, S.D.; Zhao, S., et al. Multiplexed ion beam imaging of human breast tumors. Nature Medicine 2014, 20, 436-442, doi: 10.1038 / nm.3488.

[0261] 16. Giesen, C.; Wang, H.a.O.; Schapiro, D.; Zivanovic, N.; Jacobs, A.; Hattendorf, B.;Schtiffler, P.J.; Grolimund, D.; Buhmann, 316 J.M.; Brandt, S., et al. Highly multiplexed imagingof tumor tissues with subcellular resolution by mass cytometry. Nature methods 2014, 17, 417- 422, doi : 10.1038 / nmeth.2869.

[0262] 17. Robertson, D.; Savage, K.; Reis-Filho, J.S.; Isacke, C.M. Multiple immunofluorescence labelling of formalin-fixed paraffin- embedded (FFPE) tissue. BMC Cell Biol 2008, 9, 13, doi: 10.1186 / 1471-2121-9-13.

[0263] 18. Liao, R.; Pham, T.; Mastroeni, D.; Coleman, P.D.; Labaer, J.; Guo, J. HighlySensitive and Multiplexed In-Situ Protein Profiling with Cleavable Fluorescent Streptavidin. Cells 2020, 9, doi: 10.3390 / cells9040852.

[0264] 19. Saka, S.K.; Wang, Y.; Kishi, J.Y.; Zhu, A.; Zeng, Y.; Xie, W.; Kirli, K.; Yapp, C ;Cicconet, M.; Beliveau, B.J., et al. Immuno-SABER enables highly multiplexed and amplified protein imaging in tissues. Nat Biotechnol 2019, 37, 1080-1090, doi: 10.1038 / s41587-019-0207- y-

[0265] 20. Liao, R.; Mondal, M.; Nazaroff, C.D.; Mastroeni, D.; Coleman, P.D.; Labaer, J.;Guo, J. Highly Sensitive and Multiplexed Protein Imaging With Cleavable Fluorescent Tyramide Reveals Human Neuronal Heterogeneity. Frontiers in Cell and Developmental Biology 2021, 8, doi : 10.3389 / fcell .2020.614624.

[0266] 21. Pham, T.; Liao, R.; Labaer, J.; Guo, J. Multiplexed In Situ Protein Profiling withHigh-Performance Cleavable Fluorescent Tyramide. Molecules 2021, 26, doi: 10.3390 / molecules26082206.

[0267] 22. Amir el, A.D.; Davis, K.L.; Tadmor, M.D.; Simonds, E.F.; Levine, J.H.; Bendall,S.C.; Shenfeld, D.K.; Krishnaswamy, S.; Nolan, G.P.; Pe'er, D. viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. Nat Biotechnol 2013, 31, 545-552, doi: 10.1038 / nbt.2594.

[0268] 23. Wang, F.; Flanagan, I.; Su, N.; Wang, L.C.; Bui, S.; Nielson, A.; Wu, X.; Vo, H.T.;Ma, X.J.; Luo, Y. RNAscope: A novel in situ RNA analysis platform for formalin-fixed, paraffin- embedded tissues. Journal of Molecular Diagnostics 2012, 14, 22-29, doi: 10.1016 / j.jmoldx.2011.08.002.

[0269] 24. Xiao, L.; Guo, J. Single-Cell in Situ RNA Analysis With Switchable FluorescentOligonucleotides. Frontiers in Cell and 337 Developmental Biology 2018, 6, 1-9, doi : 10.3389 / fcell .2018.00042.

[0270] 25. Xiao, L ; Guo, J. Multiplexed single-cell in situ RNA analysis by reiterative hybridization. Analytical Methods 2015, 7, 7290- 7295, doi: 10.1039 / c5ay00500k.

[0271] 26. Xiao, L.; Labaer, J.; Guo, J. Highly sensitive and multiplexed in situ RNA profding with cleavable fluorescent tyramide. cells 2021, 10.3390 / cellsl0061277, doi: 10.3390 / cells 10061277.

[0272] 27. Xiao, L.; Liao, R.; Guo, J. Highly Multiplexed Single-Cell In Situ RNA and DNAAnalysis by Consecutive Hybridization. Molecules 2020, 25, doi:10.3390 / molecules25214900.

[0273] 28. Moffitt, J.R.; Bambah-Mukku, D.; Eichhorn, S.W.; Vaughn, E.; Shekhar, K.; Perez,J.D.; Rubinstein, N.; Hao, J.; Regev, A.; Dulac, C., et al. Molecular, Spatial and Functional SingleCell Profiling of the Hypothalamic Preoptic Region. Science 2018, 362, eaau5324, doi: 10.1126 / science.aau5324.

[0274] 29. Eng, C.-H.L.; Lawson, M.; Zhu, Q.; Dries, R.; Koulena, N.; Takei, Y.; Yun, J.;Cronin, C.; Karp, C.; Yuan, G.-C., et al. Transcriptome-scale super-resolved imaging in tissues by RNA seqFISH+. Nature 2019, 568, 235-239, doi: 10.1038 / s41586- 019-1049-y.

[0275] 30. Kishi, J.Y.; Lapan, S.W.; Beliveau, B.J.; West, E.R.; Zhu, A.; Sasaki, H.M.; Saka,S.K.; Wang, Y.; Cepko, C.L.; Yin, P. SABER 351 amplifies FISH: enhanced multiplexed imaging of RNA and DNA in cells and tissues. Nature Methods 2019, 16, 533-544, doi:10.1038 / s41592- 019-0404-0.

[0276] 31. Mondal, M.; Liao, R.; Nazaroff, C.D.; Samuel, A.D.; Guo, J. Highly multiplexed single-cell in situ RNA and DNA analysis with bioorthogonal cleavable fluorescent oligonucleotides. Chemical Science 2018, 9, 2909-2917, doi: 10.1039 / C7SC05089E.

[0277] 32. Xue, M.; Wei, W .; Su, Y.; Kim, J.; Shin, Y.S.; Mai, W X , Nathanson, D.A.; Heath,J.R. Chemical methods for the simultaneous quantitation of metabolites and proteins from single cells. J Am Chem Soc 2015, 137, 4066-4069, doi: 10.1021 / jacs.5b00944.

[0278] 33. Wu, J.; Zheng, G.; Lee, L.M. Optical imaging techniques in microfluidics and their applications. Lab Chip 2012, 72, 3566-3575, doi: 10.1039 / c21c40517b.

[0279] 34. McQuin, C.; Goodman, A.; Chernyshev, V.; Kamentsky, L.; Cimini, B.A.; Karhohs,K.W.; Doan, M.; Ding, L.; Rafelski, S.M.; Thirstrup, D., et al. CellProffler 3.0: Next-generation image processing for biology. PLoS Biol 2018, 76, e2005970, doi: 10.1371 / journal.pbio.2005970.Example 3: Multiplex in situ proteins and RNAs profiling with high-performance cleavable detectable-label tyramide / styramide.

[0280] In some embodiments, the present disclosure discloses multiplex in situ proteins and RNAs profiling with high-performance cleavable detectably -labeled tyramide.

[0281] Tn some embodiments, the present disclosure discloses multiplex in situ proteins and RNAs profiling with high-performance cleavable detectably-labeled styramide.

[0282] In some embodiments, after staining protein targets with HRP conjugated antibodies and cleavable detectably-labeled tyramide, images are captured for protein profiling. Subsequently, a mild chemical reaction is applied to cleave the label (e.g. fluorophores) and deactivate HRP simultaneously. Thereafter, RNA targets are stained with HRP conjugated RNA probes and cleavable detectably-labeled tyramide, images are captured for protein profiling. Upon reiterative cycles of protein and / or RNA staining, imaging, detectably -label removal and HRP deactivation, multiplexed protein / RNA analysis can be achieved in individual cells in situ. In some embodiments, multiple RNAs and proteins are stained and imaged. In some embodiments, the RNA targets are stained and imaged before the protein targets are stained and imaged. In some embodiments, the RNA targets are stained and imaged after the protein targets are stained and imaged. In some embodiments, the RNA targets and protein targets are stained and imaged alternatively.

[0283] In some embodiments, after staining protein targets with HRP conjugated antibodies and cleavable detectably-labeled styramide, images are captured for protein profiling. Subsequently, a mild chemical reaction is applied to cleave the label (e.g. fluorophores) and deactivate HRP simultaneously. Thereafter, RNA targets are stained with HRP conjugated RNA probes and cleavable detectably-labeled styramide, images are captured for protein profiling. Upon reiterative cycles of protein and / or RNA staining, imaging, dateable-label removal and HRP deactivation, multiplexed protein / RNA analysis can be achieved in individual cells in situ. In some embodiments, multiple RNAs and proteins are stained and imaged. In some embodiments, the RNA targets are stained and imaged before the protein targets are stained and imaged. In some embodiments, the RNA targets are stained and imaged after the protein targets are stained and imaged. In some embodiments, the RNA targets and protein targets are stained and imaged alternatively.

[0284] In some embodiments, a cleavable detectably-labeled tyramide is tyramide-Ns-, having the following chemical structure, Formula (I):wherein R is a detectable marker.

[0285] In some embodiments, the cleavable detectably-labeled tyramide is tyramide-Ns-Cy5 ofFormula II:

[0286] The tyramide-N3-Cy5 of Formula II was designed and synthesized (FIG. IB) by tethering fluorophore Cy5 to tyramide through an azide-based cleavable linker. The synthesis and characterization of tyramide-N3-Cy5 is described in Example 1.

[0287] In some embodiments, a cleavable detectably-labeled styramide (CLST) comprising the compound of Formula (IV), wherein R is a detectable marker.Formula (IV).

[0288] In some embodiments, the cleavable detectably-labeled styramide is styramide-N3-Cy5 of Formula V:

[0289] In some embodiments, the cleavable detectably-labeled styramide comprises a molecule having Formula (VI):Linker-TAG

[0290] In some embodiments, X is a hydrogen. Linker is a cleavable linker having the structure of Formula III, and TAG is a detectable marker.

[0291] In some embodiments, each of the groups Rl, R2, R3, R4, R5, R6, and R7 can be one of hydroxyl group, H, alkyl, alkenyl, alkynyl, halogen, carboxy, alkoxy, aryloxy, thiol, alkylthiol, arylthiol, azido, nitro, nitroso, cyano, amino, hydroxy, phosphonyl, sulfonyl, carbonyl, boronyl, aryl or heteroaryl group. In some embodiments, Rl, R2, R3, R4, R5, R6, and R7 are the same. In some embodiments, one or more of the Rl, R2, R3, R4, R5, R6, and R7 are different from the others.

[0292] In some embodiments, the cleavable detectably-labeled styramide comprises a molecule having Formula (VII):

[0293] In some embodiments, X is a hydrogen. Linker is a cleavable linker having the structure of Formula III, and TAG is a detectable marker.

[0294] In some embodiments, each of the groups Rl, R2, R3, R4, R5, R6, R7, R8, R9, and R10 can be one of hydroxyl group, H, alkyl, alkenyl, alkynyl, halogen, carboxy, alkoxy, aryloxy, thiol, alkylthiol, arylthiol, azido, nitro, nitroso, cyano, amino, hydroxy, phosphonyl, sulfonyl, carbonyl, boronyl, aryl or heteroaryl group. In some embodiments, Rl, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are the same. In some embodiments, one or more of the Rl, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are different from the others.

[0295] In some embodiments, the cleavable detectably-labeled styramide comprises a molecule having Formula (VIII):

[0296] Tn some embodiments, X is a hydrogen. Linker is a cleavable linker having the structure of Formula III, and TAG is a detectable marker.

[0297] In some embodiments, each of the groups Rl, R2, R3, R4, R5, R6, R7, R8, R9, and RIO can be one of H, alkyl, alkenyl, alkynyl, halogen, carboxy, alkoxy, aryloxy, thiol, alkylthiol, arylthiol, azido, nitro, nitroso, cyano, amino, hydroxy, phosphonyl, sulfonyl, carbonyl, boronyl, aryl or heteroaryl group. In some embodiments, Rl, R2, R3, R4, R5, R6, R7, R8, R9, and RIO are the same. In some embodiments, one or more of the Rl, R2, R3, R4, R5, R6, R7, R8, R9, and RIO are different from the others.

[0298] Fig. 18 shows multiplex in situ proteins and RNAs profiling of human tonsil FFPE tissue with cleavable detectably-labeled tyramide / styramide. As shown in Fig. 18, the yellow stains show the PPIB (RNA) in situ hybridization, the green stains show the CD4 protein in situ hybridization, the red stains show the CD8 protein in situ hybridization, the purple stains show the FOXP3 protein in situ hybridization.

[0299] In Fig. 18, the multiplex in situ proteins and RNAs profiling of human tonsil FFPE tissue includes 1-plex RNA profiling and 3-plex protein profiling. In particular, the human tonsil FFPE tissue is first profiled with 1-plex RNA probe (PPIB) using the HCR Pro protocol described below.

[0300] A. Dewaxing Process:

[0301] (1) Baking the Slides: Place the FFPE tissue slides in an oven preheated to 60°C and incubate them for 1 hour. This baking step softens the paraffin wax, facilitating its removal in subsequent steps. If you are using an ACD HybEZ Oven, select the “Bake” setting for this process.

[0302] (2) Dewaxing the Slides (Deparaffinization):

[0303] Immerse the slides in Histo-Clear (or xylene) for 10 minutes. Repeat this immersion two to three times, using Histo-Clear (or xylene) for each cycle, to ensure complete removal of paraffin wax from the tissue sections.

[0304] After the xylene / Histo-Clear treatments, transfer the slides to 100% ethanol for 2-5 minutes to remove any residual xylene.

[0305] Allow the slides to air-dry.

[0306] Gradually rehydrate the tissue by sequentially immersing the slides in decreasing concentrations of ethanol: 90%, 50%, in sequence at 200ul twice per step. This gradual rehydration helps to prevent tissue shrinkage or distortion and prepares the tissue for subsequent staining.

[0307] After the ethanol washes, rinse the slides with DI water at 500ul for 3 times.

[0308] B. RNAscope Target Retrieval Process

[0309] (1) Heat the FFPE tissue slides to induce antigen retrieval

[0310] Set hot plate at 95 C for 5mins or until it reaches set temp.

[0311] Inject 200ul of IxRNAscope™ retrieval buffer to the FFPE tissue slides. Incubate the slides for 25mins at 95 C.

[0312] (2) Cool down the slides to room temperature.

[0313] (3) Rinse the slides with 200ul RNase / DNase free water for 3 times.

[0314] (4) Incubate the slides with 3% H2O2 for 5 minutes at room temperature.

[0315] (5) Rinse the slides with 300ul RNase / DNase free water for 3 times.

[0316] C. Staining Process: (with CFT)

[0317] (1) Reagent preparation:

[0318] Wash Solution: lx BOND wash solution (or lx RNAscope wash solution)

[0319] Probe Set: The detailed probes and its working mechanism are illustrated at www.molecularinstruments.com / technology, which is hereby incorporated by reference.

[0320] Probe A (50ul) + probe A diluent (150ul)

[0321] Probe B (50ul) + probe B diluent (150ul)

[0322] (2) Detection by the probe set: incubate the FFPE tissue slides at 45 C, (ACD HybEZOven, choose “Hold” at 45C), accordingly to the following procedure:

[0323] Incubate with 200ul of diluted probe A for 75mins at temperature of 45C.

[0324] Rinse the slides with 200 ul of Bond wash solution for 3 times at room temperature.

[0325] Incubate with 200ul of diluted probe B for 75mins at temperature of 45C.

[0326] Rinse the slides with 200 ul of Bond wash solution for 3 times at room temperature.

[0327] (3) Detection by the initiator i 1 : incubate the FFPE tissue slides at 42 C, (ACD HybEZOven, choose “Hold” at 42C), accordingly to the following procedure, and process / reagents disclosed at www.molecularinstruments.com / technology, which is hereby incorporated by reference:

[0328] Detect A: using 200 ul for incubation of slides for 3 minutes at 42 C.

[0329] Detect B: using 200 ul for incubation of slides for 60 minutes at 42 C.

[0330] Rinse the slides with 200 ul of wash solution for 3 times at room temperature.

[0331] (4) Amplification process (Hybridization-chain-reaction)

[0332] Detect C: using 200 ul for incubation of slides for 5 minutes at room temperature.

[0333] Detect D: using 200 ul for incubation of slides for 15 minutes at room temperature.

[0334] Rinse the slides with 200 ul of wash solution for 3 times at room temperature.

[0335] (5) HRP Labeling

[0336] Detect E: using 200 ul for incubation of slides for 10 minutes at room temperature.

[0337] Rinse the slides with 200 ul of wash solution for 3 times at room temperature.

[0338] Detect F: using 200 ul for incubation of slides for 15 minutes at room temperature.

[0339] Rinse the slides with 200 ul of wash solution for 3 times at room temperature.

[0340] (6) Fluorescent dye labeling:

[0341] Prepare CFT mixture in a tube: adding lul of CFT (0.05mM), 200ul TSA® amplification buffer

[0342] Incubate the slides with the CFT mixture for 30 minutes at room temperature.

[0343] Rinse the slides with 200 ul of wash solution for 3 times at room temperature.

[0344] (7) DAPI staining

[0345] Prepare DAPI staining solution: in a tube, dilute DAPI with PBS to make 200ul at a concentration of Img / ml.

[0346] Inj ect the DAPI staining solution to the slides, incubate the slides with the DAPI staining solution for 1 minute at room temperature.

[0347] Rinse the slides with 200 ul of wash solution for 3 times at room temperature.

[0348] D. Imaging Process

[0349] The imaging process is conducted in the same manner as described in Example 1 and Example 2.

[0350] E. Cleavage Process

[0351] All solutions in this process need to be made within an hour before each incubation step. Keep the test tube capped before the solutions are used.

[0352] (1). Fluorescent Removal

[0353] Cleave 1 solution:

[0354] Prepare in a tube: mix 7mg of TCEP (Cl) in 5x SSC at pH 7 (lOOmM TCEP solution)

[0355] Incubate the slides with 200 ul of Cleave 1 solution for 30 minutes at 40 C. (15 minutes for Cy3 and Cy5)

[0356] Rinse the slides with 200 ul of wash solution for 3 times at room temperature.

[0357] Cleave 2 solution:

[0358] Prepare in a tube: mix 7mg PTA (C2) in IxPBS until fully dissolve

[0359] Incubate the slides with 200 ul of Cleave 2 solution for 30 minutes at 40 C. (15 minutes for Cy3 and Cy5)

[0360] Rinse the slides with 200 ul of wash solution for 3 times at room temperature.

[0361] F. Imaging Process

[0362] The imaging process is conducted in the same manner as described in Example 1 and Example 2.

[0363] Once the staining, imaging, cleaving of the RNA targets are accomplished, the in situ profding of proteins, CD4, CD8, and FOXP3 is conducted according to the section 1.3-1.12 of the Example 1.

[0364] The materials used for the staining of the proteins CD4, CD8, and FOXP3 are listed in Table 2 below.

[0365] Table 2. Materials used for the staining of the proteins CD4, CD8, and FOXP3

[0366] Fig. 18 shows the results of the multiplex in situ proteins (CD4, CD8, and FOXP3) and RNA (PPIB) profding with cleavable detectable-label tyramide / styramide.

[0367] The foregoing description of illustrative embodiments of the invention has been presented for purposes of illustration and of description. It is not intended to be exhaustive or to limit the invention to the precise form disclosed, and modifications and variations are possible in light of the above teachings or may be acquired from practice of the invention. The embodiments were chosen and described in order to explain the principles of the invention and as practical applications of the invention to enable one skilled in the art to utilize the invention in various embodiments and with various modifications as suited to the particular use contemplated. It is intended that the scope of the invention be defined by the claims appended hereto and their equivalents.

Claims

1. CLAIMSWhat is claimed is:

1. A compound having formula (IV):wherein R comprises a detectable marker.

2. The compound of claim 1 wherein the detectable marker is selected from the group consisting of Cy5, TAMRA (labeled with tetramethylrhodamine or “TMR”), ALEXA FLUOR™ 594, and ATTO 647N and ATTO 700 fluorophores (ATTO-TEC, Germany), quantum dots, ALEXA FLUOR™ 350, ALEXA FLUOR™ 532, ALEXA FLUOR™ 546, ALEXA FLUOR™ 568, ALEXA FLUOR™ 647, BODIPY 493 / 503, BODIPY FL, BODIPY R6G, BODIPY 530 / 550, BODIPY TMR, BODIPY 558 / 568, BODIPY 558 / 568, BODIPY 564 / 570, BODIPY 576 / 589, BODIPY 581 / 591, BODIPY 630 / 650, BODIPY 650 / 665, Cascade Blue, Cascade Yellow, Dansyl, lissamine rhodamine B, Marina Blue, Oregon Green 488, Oregon Green 514, Pacific Blue, rhodamine 6G, rhodamine green, rhodamine red, tetramethyl rhodamine, DYLIGHT™ DYES (e g., DYLIGHT™ 405, DYLIGHT™ 488, DYLIGHT™ 549, DYLIGHT™ 594, DYLIGHT™ 633, DYLIGHT™ 649, DYLIGHT™ 680, DYLIGHT™ 750, DYLIGHT™ 800 and the like), Texas Red, and Cy2, Cy3.5, Cy5.5, Cy7, sulfonated Cy2, Cy3.5, Cy 5, Cy5.5, and Cy7, fluorescent proteins, and radioisotopes.

3. The compound of claim 1, wherein the detectable marker comprises a fluorophore.

4. The compound of claim 3, wherein the fluorophore is selected from the group consisting of Cy5, TAMRA, ALEXA FLUOR™ 594, ATTO 647N, and ATTO 700.

5. The compound of claim 1, wherein the compound is formula (V):

6. A method of multiplex in situ analysis of biomolecules in a tissue sample, the method comprising:(a) contacting a tissue sample with a first plurality of horseradish peroxidase (HRP)- conjugated targeting agents that are configured to specifically bind to or hybridize to a first target biomolecule in the tissue sample under conditions that promote binding or hybridization of the targeting agents to the target biomolecule;(b) contacting the tissue sample with the compound of claim 1 under conditions that promote conjugation of the compound to the target biomolecule;(c) imaging the tissue sample thereby detecting the detectable marker;(d) contacting the tissue sample with a composition comprising l,3,5-Triaza-7- phosphaadamantane (PTA) and tris(2-carboxyethyl)phosphine (TCEP);(e) repeating steps (a) - (d); wherein a second plurality of HRP -conjugated targeting agents is used to bind to or hybridize to a second target biomolecule, wherein the first and the second target biomolecules are different.

7. The method of claim 6, further comprising:(f) repeating steps (a)-(d) N times, wherein the Nth plurality of HRP-conjugated targeting agents is used to bind to or hybridize to the Nth target biomolecule, wherein the first through the Nth target biomolecules are different.

8. The method of claim 6, wherein the first plurality of targeting agents comprises HRP-conjugated synthetic DNA oligonucleotide probes.

9. The method of claim 6, wherein the first plurality of targeting agents comprises HRP-conjugated polyclonal antibodies, HRP-conjugated monoclonal antibodies, or HRP- conjugated antigen-binding fragments thereof.

10. The method of claim 6, wherein the first target biomolecules are less abundant in the sample tissue than the second target biomolecules.

11. The method of claim 6, wherein step (d) comprises incubating the contacted sample at about 40°C for about 30 minutes.

12. A kit comprising:(a) a composition comprising the compound of Formula IV(b) a composition comprising l,3,5-Triaza-7-phosphaadamantane (PTA); and(c) a composition comprising tris(2-carboxyethyl)phosphine (TCEP).

13. The kit of claim 12, further comprising:(d) horseradish peroxidase (HRP)-conjugated targeting agents.

14. The method of claim 6, comprising, after step d) and before step e), stripping the tissue sample of the HRP-conjugated targeting agent.15 The method of claim 6, comprising, after step (e),(f) stripping the tissue sample by subjecting the sample to a boiling solution; and(g) repeating steps (a) - (e).

16. The method of claim 7, comprising:(h) repeating steps (a)-(d) N times, wherein the Nth plurality of HRP-conjugated targeting agents is used to bind to or hybridize to the Nth target biomolecule, wherein the first through the Nth target biomolecules are different.

17. The method of claim 14 , further comprising:(i) repeating steps (a)-(h) N times, wherein the Nth plurality of HRP-conjugated targeting agents is used to bind to or hybridize to the Nth target biomolecule, wherein the first through the Nth target biomolecules are different.

18. The method of claim 6, wherein the first plurality of targeting agents comprises HRP-conjugated synthetic nucleic acids capable of binding or hybridizing to the first target biomolecule.

19. The method of claim 6, wherein the detectable marker comprises a dye, fhiorophore, or radioisotope.

20. The kit of claim 13, wherein the horseradish peroxidase (HRP)-conjugated targeting agents comprise: HRP-conjugated synthetic nucleic acid, HRP-conjugated synthetic aptamer, HRP-conjugated synthetic DNA oligonucleotide probe, HRP-conjugated polyclonal antibody, HRP-conjugated monoclonal antibody, or HRP-conjugated antigen-binding fragments of an antibody.21 . A method of multiplex in situ analysis of RNA targets and protein targets in a tissue sample, the method comprising:(a) contacting a tissue sample with a HCR probe set comprising at least one probes that are configured to specifically bind to or hybridize to a first RNA target in the tissue sample under conditions that promote binding or hybridization of the targeting agents to the first RNA target;(b) contacting the tissue sample with an initiator set to form an initiator target on the first RNA target;(c) contacting the tissue sample with an amplification kit;(d) contacting the tissue sample with a first plurality of horseradish peroxidase (HRP)-conjugated targeting agents that are configured to specifically bind to or hybridize to the initiator target in the tissue sample;(e) contacting the tissue sample with the compound of claim 1;(f) imaging the tissue sample thereby detecting the detectable marker;(g) contacting the tissue sample with a composition comprising l,3,5-Triaza-7- phosphaadamantane (PTA) and tris(2-carboxyethyl)phosphine (TCEP).

22. The method of claim 21 further comprises: repeating steps (a) - (g); wherein a second plurality of HRP-conjugated targeting agents is used to bind to or hybridize to a second RNA target, wherein the first and the second RNA targets are different.

23. The method of claim 22, further comprising: repeating steps (a)-(g) N times, wherein the Nth plurality of HRP-conjugated targeting agents is used to bind to or hybridize to the Nth RNA target, wherein the first through the Nth RNA targets are different.

24. The method of claim 21 further comprises:(h) contacting the tissue sample with a second plurality of horseradish peroxidase (HRP)-conjugated targeting agents that are configured to specifically bind to or hybridize to a first protein target in the tissue sample;(i) contacting the tissue sample with the compound of claim 1 under conditions that promote conjugation of the compound to the first protein target;(j) imaging the tissue sample thereby detecting the detectable marker;(k) contacting the tissue sample with a composition comprising l,3,5-Triaza-7- phosphaadamantane (PTA) and tris(2-carboxyethyl)phosphine (TCEP);25. The method of claim 24 further comprises: repeating steps (h) - (k); wherein a second plurality of HRP-conj ugated targeting agents is used to bind to or hybridize to a second protein target, wherein the first and the second protein targets are different.

26. The method of claim 25, further comprising: repeating steps (h)-(k) N times, wherein the Nth plurality of HRP-conj ugated targeting agents is used to bind to or hybridize to the Nth protein target, wherein the first through the Nth protein targets are different.

Images